VTE GWAS

1 Title: Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors 2 3 Florian Thibord PhD^{1,2*}, Derek Klarin MD^{3*}, Jennifer A. Brody BA⁴, Ming-Huei Chen PhD^{1,2}, Michael G. Levin MD^{5,6}, Daniel I. Chasman PhD^{7,8}, Ellen L. Goode PhD MPH⁹, Kristian Hveem 4 PhD^{10,11}, Maris Teder-Laving MSc¹², Angel Martinez-Perez MSc¹³, Dylan Aïssi PhD^{14,15}, Delphine 5 Daian-Bacg PhD^{16,17}, Kaoru Ito PhD MD¹⁸, Pradeep Natarajan MD MMSc^{19,20,21}, Pamela L. Lutsey

- 6 PhD²², Girish N. Nadkarni MD MPH^{23,24,25}, Gabriel Cuellar-Partida PhD²⁶, Brooke N. Wolford 7
- PhD²⁷, Jack W. Pattee PhD^{28,29}, Charles Kooperberg PhD³⁰, Sigrid K. Braekkan PhD^{31,32}, Ruifang 8
- Li-Gao PhD³³, Noemie Saut PhD³⁴, Corriene Sept PhD³⁵, Marine Germain MS^{14,15,17}, Renae L. 9
- Judy MS³⁶, Kerri L. Wiggins MS RD⁴, Darae Ko MD^{37,2}, Christopher O'Donnell MD MPH³⁸, Kent D. 10
- Taylor PhD³⁹, Franco Giulianini PhD⁷, Mariza De Andrade PhD⁹, Therese H. Nøst PhD¹¹, Anne 11
- Boland PhD^{16,17}, Jean-Philippe Empana PhD^{40,41}, Satoshi Koyama PhD MD^{18,42,19}, Thomas 12
- Gilliland MD^{19,42,21}, Ron Do PhD^{23,24,43}, Xin Wang PhD²⁶, Wei Zhou PhD⁴⁴, Jose Manuel Soria 13
- PhD¹³, Juan Carlos Souto MD PhD^{45,13}, Nathan Pankratz PhD⁴⁶, Jeffery Haessler MS³⁰, Kristian 14
- Hindberg PhD³¹, Frits R. Rosendaal MD PhD⁴⁷, Constance Turman MS³⁵, Robert Olaso PhD^{16,17}, 15 Rachel L. Kember MSc PhD⁴⁸, Traci M. Bartz MS⁴⁹, Julie A. Lynch PhD RN MBA^{50,51}, Susan R.
- 16 Heckbert MD MPH⁵², Sebastian M. Armasu MS⁹, Ben Brumpton PhD¹¹, David M. Smadja MD
- 17
- PhD^{53,54}, Xavier Jouven MD PhD^{40,41}, Issei Komuro PhD MD⁵⁵, Katharine Clapham MD^{56,20,21}, Ruth 18 J.F. Loos PhD²³, Cristen Willer PhD²⁷, Maria Sabater-Lleal PhD^{13,57}, James S. Pankow PhD²², 19
- Alexander P. Reiner MD MSc^{58,30}, Vania M. Morelli MD PhD^{31,32}, Paul M. Ridker MD MPH^{7,8}, 20
- Astrid van Hylckama Vlieg PhD⁴⁷, Jean-François Deleuze PhD^{16,59,60}, Peter Kraft PhD³⁵, Daniel J. 21
- 22 Rader MD⁶¹, Barbara McKnight PhD⁴⁹, Global Biobank Meta-Analysis Initiative, Estonian Biobank
- 23 Research Team, 23andMe Research Team, Kyung Min Lee PhD⁵⁰, Bruce M. Psaty MD PhD^{4,62,63},
- Anne Heidi Skogholt PhD¹¹, Joseph Emmerich MD PhD^{64,65}, Pierre Suchon MD PhD^{34,66}, Biobank 24
- Japan⁶⁷, Stephen S. Rich PhD⁶⁸, Ha My T. Vy PhD^{23,24}, Weihong Tang MD PhD⁶⁹, Rebecca D. 25
- Jackson MD⁷⁰, John-Bjarne Hansen MD PhD^{31,32}, Pierre-Emmanuel Morange MD PhD^{34,66}, 26
- Christopher Kabrhel MD MPH^{71,72}, David-Alexandre Trégouët PhD^{14,15,17*}, Scott Damrauer 27
- MD⁶*, Andrew D. Johnson PhD^{1,2}*, Nicholas L. Smith PhD^{49,73}* 28
- 29
- 30 *Denotes equal contribution
- 31
- 32 ¹Population Sciences Branch, Division of Intramural Research, National Heart, Lung and Blood
- 33 Institute, 73 Mt. Wayte, Suite #2, Framingham, MA, 01702, USA,
- 34 ²The Framingham Heart Study, Boston University and NHLBI, 73 Mt. Wayte Ave, Suite #2,
- 35 Framingham, MA, 01702, USA,
- 36 ³Division of Vascular Surgery, Stanford University School of Medicine, Palo Alto, CA, 94305,
- 37 USA,
- 38 ⁴Cardiovascular Health Research Unit, Department of Medicine, University of Washington, 1730
- 39 Minor Ave, Suite 1360, Seattle, WA, 98101, USA,
- 40 ⁵Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania, 3400
- 41 Spruce Street, PA, 19104, USA,
- 42 ⁶Medicine, Copora Michael J. Crescenz Philadelphia VA Medical Center, 3900 Woodland Ave,
- 43 PA, 19104, USA,

- ⁷Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave,
- 45 Boston, MA, 02215, USA,
- 46 ⁸Harvard Medical School, Boston, MA, 02115, USA,
- ⁹Department of Quantitative Health Sciences, Mayo Clinic, 200 First Street SW, Rochester, MN,
- 48 55905, USA,
- 49 ¹⁰HUNT Research Center, Department of Public Health and Nursing, Norwegian University of
- 50 Science and Technology, Forskningsvegen 2, Levanger, 7600, Norway,
- ⁵¹ ¹¹K.G. Jebsen Centre for Genetic Epidemiology, Department of Public Health and Nursing,
- 52 Norwegian University of Science and Technology, Håkon Jarls gate 11, Trondheim, 7030,
- 53 Norway,
- ¹²Institute of Genomics, University of Tartu, Riia 23b, Tartu, Tartu, 51010, Estonia,
- ¹³Genomics of Complex Disease Unit, Sant Pau Biomedical Research Institute (IIB Sant Pau),
- 56 Barcelona, Spain, St Quinti 77-79, Barcelona, 8041, Spain,
- ¹⁴Bordeaux Population Health Research Center, University of Bordeaux, 146 rue Léo Saignat,
- 58 Bordeaux, 33076, France,
- ¹⁵UMR1219, INSERM, 146 rue Léo Saignat, Bordeaux, 33076, France,
- ¹⁶Centre National de Recherche en Génomique Humaine, CEA, Université Paris-Saclay, 2 Rue
- 61 Gaston Crémieux, Evry, 91057, France,
- 62 ¹⁷Laboratory of Excellence on Medical Genomics, France,
- 63 ¹⁸Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical
- 64 Sciences,, 1-7-22 Suehirocho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan,
- ¹⁹Cardiovascular Research Center, Massachusetts General Hospital, 185 Cambridge Street,
- 66 Boston, MA, 02446, USA,
- ²⁰Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad
- 68 Institute of Harvard & MIT, 75 Ames St, Cambridge, MA, USA,
- ²¹Department of Medicine, Harvard Medical School, Shattuck St, Boston, MA, USA,
- 70 ²²Division of Epidemiology and Community Health, University of Minnesota, 1300 South Second
- 71 Street, MN, 55454, USA,
- 72 ²³The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount
- 73 Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA,
- ²⁴Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1
- 75 Gustave L. Levy Pl, New York, NY, 10029, USA,
- ²⁵Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1
- 77 Gustave L. Levy Pl, New York, NY, 10029, USA,
- ²⁶23andMe, Inc., 223 N Mathilda Ave, CA, 94086, USA,
- 79 ²⁷Department of Computational Medicine and Bioinformatics, University of Michigan, Ann
- 80 Arbor, MI, 48109, USA,
- ²⁸Division of Biostatistics, University of Minnesota, 420 Delaware St. SE, MN, 55455, USA,
- 82 ²⁹Center for Innovative Design & Analysis and Department of Biostatistics & Informatics,
- 83 Colorado School of Public Health, 13001 East 17th Place, CO, 80045, USA,
- ³⁰Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview
- 85 Ave N, Seattle, WA, 98109, USA,
- ³¹Thrombosis Research Center (TREC), UiT The Arctic University of Norway, Universitetsvegen
- 87 57, Tromsø, 9037, Norway,

- ³²Division of internal medicine, University Hospital of North Norway, Tromsø, 9038, Norway,
- ³³Clinical Epidemiology, Leiden University Medical Center, PO Box 9600, 2300 RC, The
- 90 Netherlands,
- ³⁴Hematology Laboratory, La Timone University Hospital of Marseille, 264 Rue Saint-Pierre,
- 92 Marseille, 13385, France,
- 93 ³⁵Department of Epidemiology, Harvard TH Chan Harvard School of Public Health, 655
- 94 Huntington Ave., Building II, Boston, MA, 02115, USA,
- 95 ³⁶Surgery, University of Pennsylvania, 3401 Walnut Street, PA, 19104, USA,
- 96 ³⁷Section of Cardiovascular Medicine, Boston University School of Medicine, 85 East Newton
- 97 Street, Boston, MA, 02118, USA,
- 98 ³⁸Cardiology, VA Boston Healthcare System, Boston, MA, 02130, USA,
- ³⁹Institute for Translational Genomics and Population Sciences, The Lundquist Institute for
- 100 Biomedical Innovation, 1124 W Carson St., Torrance, CA 90502, CA, USA,
- ⁴⁰Integrative Epidemiology of cardiovascular diseases, Université Paris Descartes, Sorbonne
- 102 Paris Cité, 56 rue Leblanc, Paris, 75015, France,
- ⁴¹Paris Cardiovascular Research Center, Inserm U970, Université Paris Descartes, Sorbonne
- 104 Paris Cité, 20 rue Leblanc, Paris, 75015, France,
- ⁴²Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad
 Institute of Harvard & MIT, 75 Ames St, Cambridge, MA, 02142, USA,
- ⁴³BioMe Phenomics Center, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New
 York, NY, 10029, USA,
- ⁴⁴Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General
- 110 Hospital, 55 Fruit Street, Boston, MA, 02114, USA,
- ⁴⁵Unit of Thrombosis and Hemostasis, Hospital de la Santa Creu i Sant Pau, St Quinti 89,
- 112 Barcelona, 8041, Spain,
- ⁴⁶Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St.
- 114 SE, MN, 55455, USA,
- ⁴⁷Clinical Epidemiology, Leiden University Medical Center, PO Box 9600, Leiden, The
- 116 Netherlands,
- ⁴⁸Psychiatry, University of Pennsylvania, 3401 Walnut Street, PA, 19104, USA,
- ⁴⁹Cardiovascular Health Research Unit, Departments of Biostatistics and Medicine, University of
- 119 Washington, 1730 Minor Ave, Suite 1360, Seattle, WA, 98101, USA,
- ⁵⁰VA Informatics & Computing Infrastructure, VA Salt Lake City Healthcare System, 500 Foothills
 Drive, UT, 01730, USA,
- ⁵¹Epidemiology, University of Utah, 500 Foothills Drive, UT, 01730, USA,
- ⁵²Department of Epidemiology, University of Washington, 1730 Minor Ave, Suite 1360, Seattle,
- 124 WA, 98101, USA,
- ⁵³Hematology Department and Biosurgical Research Lab (Carpentier Foundation), European
- 126 Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, 20 rue Leblanc, Paris,
- 127 75015, France,
- ⁵⁴Innovative Therapies in Haemostasis, INSERM, Université de Paris, 4 avenue de l'Observatoire,
- 129 Paris, 75270, France,
- ⁵⁵Department of Cardiovascular Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo,
- 131 Tokyo, 113-8655, Japan,

- ⁵⁶Division of Cardiovascular Medicine, Brigham & Women's Hospital, MA, USA,
- 133 ⁵⁷Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Center for
- 134 Molecular Medicine, Stockholm, 17176, Sweden,
- ⁵⁸Department of Epidemiology, University of Washington, 3980 15th Ave NE, WA, 98195, USA,
- 136 ⁵⁹Centre D'Etude du Polymorphisme Humain, Fondation Jean Dausset, 27 rue Juliette Dodu,
- 137 Paris, 75010, France,
- 138 ⁶⁰Laboratory of Excellence on Medical Genomics,
- ⁶¹Cardiology, Medical Genetics, University of Pennsylvania, 3401 Walnut Street, PA, 19104,
 USA,
- ⁶²Department of Epidemiology, University of Washington, 1730 Minor Ave, Suite #1360, Seattle,
 WA, 98101, USA,
- ⁶³Department of Health Systems and Population Heath, University of Washington, 1730 Minor
 Ave, Suite #1360, Seattle, WA, USA,
- ⁶⁴Department of vascular medicine, Paris Saint-Joseph Hospital Group, University of Paris, 185
- 146 rue Raymond Losserand, Paris, 75674, France,
- 147 ⁶⁵UMR1153, INSERM CRESS, 185 rue Raymond Losserand, Paris, 75674, France,
- ⁶⁶C2VN, INSERM, INRAE, Aix-Marseille University, 27, bd Jean Moulin, Marseille, 13385, France,
- 149 ⁶⁷Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo,
- 150 Tokyo, 108-8639, Japan,
- ⁶⁸Center for Public Health Genomics, University of Virginia, 3242 West Complex, Charlottesville,
- 152 VA, 22908-0717, USA,
- ⁶⁹Division of Epidemiology and Community Health, University of Minnesota, 1300 South Second
 Street, MN, 55454, USS,
- ⁷⁰College of Medicine, Ohio State University, 376 W. 10th Ave, Columbus, OH, 43210, USA,
- ⁷¹Emergency Medicine, Massachusetts General Hospital, Zero Emerson Place, Suite 3B, Boston,
 MA, 02114, USA,
- ⁷²Emergency Medicine, Harvard Medical School, Zero Emerson Place, Suite 3B, Boston, 02114,
 MA,
- 160 ⁷³Department of Surgery, Perelman School of Medicine University of Pennsylvania,
- 161 Philadelphia, PA, 19104, USA
- 162
- 163 **Contact**: Nicholas L. Smith, Department of Epidemiology, University of Washington,
- 164 Seattle WA, 98195, USA. (nlsmith@u.washington.edu)
- 165
- 166 Keywords: venous thrombosis, venous thromboembolism, genetic, genome-wide
- 167 association studies, transcriptome-wide association study
- 168
- 169 Version: February 17, 2022

VTE GWAS

170 ABSTRACT

171

172 Venous thromboembolism (VTE) is a complex disease with environmental and genetic 173 determinants. We present new cross-ancestry meta-analyzed genome-wide association study 174 (GWAS) results from 30 studies, with replication of novel loci and their characterization through 175 in silico genomic interrogations. In our initial genetic discovery effort that included 55,330 176 participants with VTE (47,822 European, 6,320 African, and 1,188 Hispanic ancestry), we 177 identified 48 novel associations of which 34 replicated after correction for multiple testing. In 178 our combined discovery-replication analysis (81,669 VTE participants) and ancestry-stratified 179 meta-analyses (European, African and Hispanic), we identified another 44 novel associations, 180 which are new candidate VTE-associated loci requiring replication. In total, across all GWAS 181 meta-analyses, we identified 135 independent genomic loci significantly associated with VTE 182 risk. We also identified 31 novel transcript associations in transcriptome-wide association 183 studies and 8 novel candidate genes with protein QTL Mendelian randomization analyses. In 184 silico interrogations of hemostasis and hematology traits and a large phenome-wide association 185 analysis of the 135 novel GWAS loci provided insights to biological pathways contributing to 186 VTE, indicating that some loci may contribute to VTE through well-characterized coagulation 187 pathways while others provide new data on the role of hematology traits, particularly platelet 188 function. Many of the replicated loci are outside of known or currently hypothesized pathways 189 to thrombosis. In summary, these findings highlight new pathways to thrombosis and provide 190 novel molecules that may be useful in the development of antithrombosis treatments with 191 reduced risk of bleeds.

VTE GWAS

192 **INTRODUCTION**

193 Venous thrombosis is a vascular event resulting from an imbalance in the regulation of 194 hemostasis, with subsequent pathologic coagulation and vascular thrombosis formation. 195 Clinically, venous thrombosis can manifest as deep vein thrombosis (DVT), when occurring in 196 the deep veins primarily of the legs and trunk, or as a pulmonary embolism (PE), when the 197 thrombus embolizes and obstructs the pulmonary arteries. Collectively, these events are known 198 as venous thromboembolism (VTE), a life-threatening condition with an incidence of 1-2 events 199 per 1,000 person-years.¹⁻³ VTE is a complex disease with both environmental and genetic 200 determinants. Family studies, candidate-gene approaches, and early genome-wide association 201 studies (GWAS) primarily identified genetic risk factors in loci with well characterized effects on 202 coagulation (F2, F5, F11, FGG, ABO, SERPINC1, PROCR, PROC, PROS1), supporting current therapeutic strategies that mainly target the coagulation cascade.^{4–8} In recent years, larger 203 GWAS meta-analyses revealed unanticipated loci, such as *SLC44A2*.⁹ which was later 204 characterized as a choline transporter involved in platelet activation,¹⁰ and in the adhesion and 205 206 activation of neutrophils.^{11,12} Thus, genetic associations with VTE in larger and more diverse 207 populations may uncover new biological pathways and molecular events contributing to the 208 disease and potentially help identify novel targets for treatment. Most recently, 2 large efforts 209 involving up to 30,000 VTE cases, led by the International Network Against Venous Thrombosis (INVENT) consortium ¹³ and the Million Veteran Program¹⁴ (MVP), identified up to 43 genetic 210 211 loci associated with VTE. To expand discovery of novel VTE risk loci, we conducted a large, 212 cross-ancestry GWAS meta-analysis involving more than 80,000 VTE cases, along with a 213 replication of novel loci and their characterization through downstream analyses. 214

215 METHODS

216 Design and Study Participants

The current cross-ancestry GWAS meta-analysis is comprised of new analyses of data from 13
studies, including the Department of Veterans Affairs Million Veteran Program (MVP, version
4),¹⁴ UK Biobank (UKB), ^{15,16} FinnGen (freeze 5), Estonian Biobank (EGP),¹⁷ Biobank Japan
(BBJ),¹⁸ Mass General Brigham biobank (MGB),¹⁹ BioMe, Penn Medicine BioBank (UPenn),

VTE GWAS

- FARIVE,²⁰ MARTHA12,²¹ RETROVE,²² Multi-Ethnic Study of Atherosclerosis (MESA),²³ and
 GAIT2,^{24,25} as well as previously published data from the INVENT consortium, a 17 study analysis
- 223 of prospective cohorts and case-control data (designated INVENT-2019).¹³ A detailed
- description of participating studies is provided in supplemental **Table S1**.
- 225

226 The study design (see Figure 1) included a discovery meta-analysis of GWAS summary data 227 from 4 consortium/studies (INVENT-2019, MVP, FinnGen, EGP) followed by a replication of discovery loci that exceed the genome-wide significance threshold ($P < 5.00 \times 10^{-8}$). Included in 228 229 the replication were the remaining 10 participating studies plus 2 external collaborations that provided association results for the gueried variants: 23andMe²⁶ and Global Biobank Meta-230 Analysis Initiative (GBMI), limiting data to non-overlapping studies with our discovery.²⁷ The 231 232 combined discovery and replication data (with the exception of 23andMe and GBMI) were then 233 meta-analyzed, and ancestry-stratified meta-analyses were performed for African (AFR)-234 ancestry, European (EUR)-ancestry, and Hispanic (HIS) participants to enable further 235 downstream ancestry-specific analyses, such as fine mapping. Participants from studies 236 provided written informed consent for use of their genetic and health information for analysis, 237 and the studies were individually approved by the appropriate Institutional Review Boards (see

238 Supplemental Methods).

239

240 Study-specific GWAS

Genotyping arrays, imputation panels, and analyses performed by each participating study are
detailed in supplemental **Table S1**. Briefly, studies performed association analyses (logistic
regression analyses or generalized mixed models for case-control studies and Cox regression for
cohort studies) using age and sex as covariates and further adjusting for participant
relatedness, genetic principal components, and study site or other study-specific factors when
applicable.

247

- 248 For each dataset, quality control was performed using EasyQC²⁸ to remove variants with
- 249 missing information (effect and/or standard error), low imputation quality (< 0.3), and rare

VTE GWAS

- variants (allele count < 5). For studies missing either imputation quality or variant frequency
- 251 (BioMe, UPenn), a filter was added to remove variants with extreme effects (|Effect| > 10).
- 252 Indels and marker names were then harmonized across all studies.
- 253
- 254 For the X chromosome, all studies performed sex-stratified GWAS, excluding variants from
- 255 pseudo-autosomal regions. Results from males and females were then meta-analyzed.
- 256

257 Discovery, Replication, and Combined GWAS Meta-analyses

All GWAS meta-analyses were conducted with METAL,²⁹ using a fixed-effects inverse-variance 258 259 weighted model. All variants were included and there was no lower minor allele frequency (MAF) limit beyond study-specific minor allele count. Genome-wide significant variants (P < 260 261 5.00×10^{-8}) were kept if a concordant effect direction was observed in 2 or more studies and 262 grouped into the same locus if they were within 1Mb. We used the closest gene to the lead 263 variant to refer to each locus, except at known loci where the causal gene has been previously 264 identified and is different from the closest gene (such as PROCR or PROS1). We defined a locus 265 as novel if a genetic association with VTE has not been previously observed in the region according to our review of peer-reviewed published reports. We used PhenoGram³⁰ to visually 266 267 represent the genomic position of the loci, their significance in EUR- or AFR-ancestry analyses, 268 and their discovery status of novel or known.

269

<u>Discovery Meta-Analysis</u>: For the discovery cross-ancestry GWAS meta-analysis, we meta analyzed data from 4 consortium/studies: INVENT-2019, MVP, FinnGen and EGCUT. Participants
 were adult men and women and included 55,330 VTE cases (either DVT and/or PE cases) and
 1,081,973 controls of EUR, AFR, or HIS ancestries. At each locus with a genome-wide significant
 signal, the lead variant was extracted and tested in an independent replication meta-analysis.

<u>Replication</u>: The replication GWAS meta-analysis consisted of the remaining 10 participating
 studies, as well as 2 external collaborators (GBMI ²⁷ and 23andMe²⁶), for a total of 91,230 VTE
 cases in replication. Replicating variants from the discovery were defined as those that had

VTE GWAS

concordant effect direction in the discovery and the replication, and reached a Bonferronicorrected p-value threshold in the replication population corresponding to the number of

variants tested for replication with a 1-sided hypothesis: p-value threshold = [(0.05*2)/number

of variants tested for replication] in the replication analysis.

283

Combined GWAS Meta-Analysis and Stratification by Ancestry: We performed a combined, 284 cross-ancestry GWAS meta-analysis of discovery and replication data using participating studies 285 286 with genome-wide summary data. We included variants with MAF \geq 0.01 to maintain adequate 287 statistical power by reducing the number of low-powered tests since replication was not 288 available. Genome-wide data from GBMI and 23andMe data were not available and therefore excluded from combined analyses. We estimated the heterogeneity associated with each 289 variant using Cochran's Q test and the corresponding I² statistic. We assessed the genomic 290 inflation with the lambda genomic control.³¹ We report on variants exceeding the genome-wide 291 292 threshold ($P < 5.00 \times 10^{-8}$) and view these as candidate novel loci associated with VTE and 293 needing future replication.

294

295 We then stratified the analyses by ancestry and limited strata to EUR, AFR, and HIS ancestries 296 as the remaining ancestries had too few VTE events to be informative: East Asian (EAS) in BBJ, 297 n=507 VTE events; South Asian (SAS) in UKB, n=189 VTE events. As above, we estimated 298 heterogeneity and assessed inflation with lambda genomic control; the LD-score intercept was computed for EUR-ancestry analysis, using the recommended Hapmap3 variants.³² We report 299 all additional ancestry-specific variants exceeding the genome-wide threshold ($P < 5.00 \times 10^{-8}$) 300 301 and view these as ancestry-specific candidate loci associated with VTE and needing future 302 replication.

303

304 Ancestry-Stratified Analyses: Conditional Analyses and Fine-mapping

To estimate the presence of multiple independent signals, we performed conditional analyses
 with GCTA-COJO³³ at each locus with significant signals in the EUR- and AFR-ancestry GWAS

307 meta-analyses. The Trans-Omics for Precision Medicine (TOPMed) trans-ancestry sequence

VTE GWAS

308 data (freeze 8) was used as reference panel, selecting only EUR-ancestry participants from 309 TOPMed (N=34,890) for the EUR conditional analyses and AFR-ancestry participants (N=17,322) for the AFR analyses.³⁴ GCTA-COJO analyses were not performed for the HIS-ancestry stratum 310 since a HIS reference panel was not available in TOPMed. Conditional analyses were performed 311 312 at each locus, using a window that encompassed at least the genome-wide significant variants 313 present in the locus with an additional buffer of ±100 Kb. A stepwise joint regression model was used to identify secondary signals with joint p-values $< 5.00 \times 10^{-8}$ and a linkage disequilibrium 314 (LD) $r^2 < 0.2$ with selected variants. 315

316

317 In addition, for each locus and for each ancestry-specific GWAS meta-analysis, we produced forest plots with the *forestplot* R library, and regional association plots with the *RACER*³⁵ and 318 LDlinkR³⁶ R libraries, to visually inspect the local genetic architecture (available as supplemental 319 320 Figures 1-8). We used the 1000 Genomes project EUR-ancestry dataset as reference panel to 321 infer LD patterns for the EUR-ancestry participants and overall meta-analyses and the 1000 322 Genomes project AFR-ancestry reference panel for the AFR-ancestry meta-analysis. 323 Furthermore, at each locus where distinct lead variants were identified in the different meta-324 analyses, we also extracted the lead variant from each analysis, as well as additional 325 independent variants identified by the conditional analyses, and computed the LD between 326 each variant (using both EUR- and AFR-ancestry reference panels) to verify the independence of 327 the signals.

328

329 Transcriptome-wide Association Studies (TWAS)

We performed TWAS with the FUSION pipeline to accomplish 2 tasks: (1) prioritize genes for
 those genome-significant signals with ambiguous gene associations; and (2) identify new
 candidate loci by linking gene expression with VTE risk using GWAS results not reaching
 genome-wide significance.³⁷ This analysis was performed using the EUR-ancestry autosomal
 GWAS meta-analysis results, since FUSION depends on a EUR-ancestry LD reference panel (from
 1000 genomes³⁸) and does not include data for chromosome X. We first performed a series of
 single-tissue TWAS using gene expression from eQTL datasets relevant to blood and thrombosis

VTE GWAS

disorders: whole blood, liver, lung, and spleen from GTEx v8,³⁹ whole blood from the Young 337 338 Finn Study,⁴⁰ and peripheral blood from the Netherlands Twins Register.⁴¹ We then also employed an analysis using cross-tissue weights computed from GTEx v8 tissues, available as 3 339 340 canonical vectors (sCCA1-3) that capture most of the gene expression.⁴² All associations reaching a Bonferroni corrected significance threshold corresponding to the number of gene 341 342 tested (N=14,219, P < 3.52×10^{-6}) were deemed statistically significant. As several genes can be associated at the same locus, the TWAS results were subjected to a conditional analysis 343 implemented in FUSION to select genes that remained conditionally independent. For each 344 345 tissue, we further performed a colocalization test with COLOC⁴³ for all significant associations, 346 to identify and select genetic signals shared by both VTE risk and gene expression with high 347 posterior probability (PP4 > 0.75). Selected genes located farther than 200kb from genetic loci 348 identified in the meta-analyses were considered novel candidate VTE genes.

349

350 **Protein QTL Mendelian Randomization**

351 Using the combined, cross-ancestry VTE GWAS meta-analysis results, we performed a 352 proteome Mendelian randomization (MR) analysis with high-confidence genomic instruments 353 corresponding to protein QTL (pQTL) for 1,216 circulating plasma proteins that passed consistency and pleiotropy filters, as previously described.⁴⁴ When 2 or more genetic 354 355 instruments were available for the exposure-outcome pairs, we performed inverse variance-356 weighted MR. If a single genetic variant was present, Wald-ratio MR was used instead. In 357 addition, when multiple SOMAmers for a protein were available, which was the case for 40 358 proteins, tests were conducted separately for each SOMAmer. To account for multiple testing, 359 associations passing the Bonferroni corrected threshold corresponding to the number of 360 SOMAmers tested (N=1,256, $P < 3.98 \times 10^{-5}$) were considered statistically significant.

361

362 Association of VTE Loci with Hemostasis and Hematology Traits

363 We conducted a series of *in silico* investigations involving hemostasis and hematology traits to

- 364 better characterize the VTE-associated variants from the GWAS meta-analyses. To better
- 365 understand if novel VTE-associated variants might operate through hemostasis pathways, we

VTE GWAS

extracted associations from published GWAS of 10 hemostatic traits: fibrinogen;⁴⁵ fibrin Ddimer;⁴⁶ coagulation factors VII (FVII),⁴⁷ VIII (FVIII),⁴⁸ and XI (FXI);⁴⁹ von Willebrand factor
(vWF);⁴⁸ tissue plasminogen activator (tPA);⁵⁰ plasminogen-activator inhibitor 1 (PAI-1);⁵¹
activated partial thromboplastin time (aPTT); and prothrombin time (PT).⁵² Since each variantassociation was investigated in 10 hemostasis traits, we set a p-value threshold of 0.005
(0.05/10 traits tested for each lead variant of a locus) to separate associations of interest from
other associations.

373

Similarly, we extracted associations with complete blood count (CBC) measures using summary data from nearly 750,000 individuals on 15 leukocyte, erythrocyte, and platelet traits.⁵³ Given the large sample size and high statistical power of these analyses, we used a more stringent threshold of interest that was a Bonferroni correction corresponding to the number of look-ups performed ($P < 1.92 \times 10^{-5}$).

379

380 Phenome-wide Association Testing

381 To explore associations between VTE-associated variants and other traits agnostically, we

382 performed a phenome-wide association study (PheWAS) using the MRC IEU infrastructure,⁵⁴

383 which included the datasets from the 1,500 UKB analyses performed by the Neale lab on

384 337,000 individuals of British ancestry (pheWAS source codes: ukb-a and ukb-d). Only variants

of interest reaching genome-wide significance (P < 5.00 x 10⁻⁸) were extracted for each trait and
 presented.

387

388 RESULTS

389 Discovery Cross-Ancestry Meta-analysis and Replication

390 The primary cross-ancestry discovery analysis was based on 4 contributing consortium/studies

- 391 (INVENT-2019, MVP, FinnGen, EGP) and included 55,330 participants among 3 ancestry groups
- with VTE (47,822 EUR, 6,320 AFR, and 1,188 HIS) and 1,081,973 participants without VTE
- 393 (918,195 EUR, 118,144 AFR, and 45,634 HIS). Over the 22 autosomal and X chromosomes, 35.5
- 394 million variants were analyzed, and the observed genomic inflation factor was 1.06. We

VTE GWAS

identified 10,493 variants reaching genome-wide significance, corresponding to 85 loci, of
which 48 have not been identified in previous genetic studies of VTE (see supplemental Table
S2).

398

399 We tested these 85 variants for replication in 91,230 cases and 3,322,939 controls from the independent replication data. After meta-analyzing the results of these 85 tests in the 400 401 replication population, we identified 83 variants with a concordant effect direction between the 402 discovery and the replication, of which 68 replicated at the 1-sided Bonferroni corrected 403 significance threshold (p < 0.1/83 = 0.0012) (Table 1, Figure 2, supplemental Table S2). The 404 successfully replicated signals corresponded to 34 known and 34 novel loci. Among the 34 novel 405 loci that replicated, heterogeneity was minimal (heterogeneity P > 0.05), odds ratios (ORs) 406 ranged between 0.84-0.98 and 1.03-1.18, and MAFs were all ≥ 0.021. The majority of variants 407 were gene-centric (4 exonic, 16 intronic, and 3 in 3' or 5' UTR regions or immediately 408 downstream), 3 were linked to intronic non-coding RNA, and 8 were considered intergenic. The 409 novel replicated variants were at the following loci (in chromosomal order): H6PD/SPSB1, 410 TENT5C, TRIM58, CALCRL (near TFPI), CPS1, SERPINE2, PIK3CB/LINC01391, MECOM, 411 LINC01968/XXYLT1, SEC31A, ARHGAP24, LNPEP, ILRUN, AGPAT5/XKR5, ZNF367/HABP4, MIR1265/FAM107B, ZMIZ1, PLCE1, ST3GAL4, A2ML1/PHC1, COPZ1, SH2B3, RCOR1, MAP1A, 412 413 RORA-AS1, HSD3B7, ZFPM1, ALOX12-AS1, MAPT-AS1, CEP112/APOH, RFX2, GIPR, FUT2, and 414 SYN3. Among the 17 variants and their associated loci that failed replication, 14 were novel and 415 remain candidate loci that merit additional replication while 3 were known loci: PROS1, JAK2, 416 and STAB2.

417

418 Combined Cross-Ancestry GWAS Meta-analysis and Ancestry-Stratified Results

419 <u>Combined</u>: The combined, cross-ancestry meta-analysis of the studies with genome-wide

420 markers included 81,669 individuals with VTE and 1,426,717 individuals without VTE. We

- 421 analyzed 19.1 million common variants (MAF \geq 0.01) and observed a genomic factor of 1.16
- 422 which is slightly elevated but expected for large scale meta-analyses of polygenic traits.⁵⁵ We
- 423 identified 16,550 variants reaching genome-wide significance located in 110 loci, of which 41

VTE GWAS

424 were not observed in the discovery analysis (supplemental Table S3, Figure 2). Of these 41 425 additional loci, 1 corresponded to a common variant at the known SERPINC1 locus (rs6695940) 426 which encodes antithrombin, 4 were previously identified in the INVENT-2019¹³ or MVP¹⁴ meta-427 analyses at the PEPD, ABCA5, MPHOSPH9, and ARID4A loci, and 1 was a known pathogenic missense variant located in SERPINA1 (rs28929474, p.Glu366Lys).⁵⁶ The remaining 35 loci were 428 429 novel associations and are presented in Table 2. Among the 35 candidate loci, all had ORs 430 within the range of 0.93-0.97 and 1.03-1.15 and had a minimum MAF of 0.021. The majority of 431 the variants were gene-centric (18 intronic and 3 in 3' UTR regions), 3 were intronic in non-432 coding RNA and 11 were considered intergenic. These candidate loci included (in chromosomal 433 order): ARID1A, AK5, CELSR2, FALEC/ADAMTSL4, DCST2, FCER1G, CFHR1/CFHR4, LINC01800, RFTN2/MARS2, LINC02029/LINC00880, AFAP1, REST, ARHGEF28, HSPA4, CARMIL1, HCG9, 434 435 JAZF1-AS1, LOC101929128/LOC157273, ENTPD4/SLC25A37, RBPMS, ANGPT1, MLLT10, 436 RAB18/MKX. SOX6. MS4A4A/MS4A6E. ZBTB16. SNX19. LINC02324/MIR4708. 437 LINC00924/LOC105369212, NDE1, DHODH/HP, CFDP1, C16orf74, TAOK1, and RAB4B. 438 439 European Ancestry: The EUR-ancestry meta-analysis, which included 71,771 participants with 440 VTE and 1,059,740 participants without VTE, had a lambda genomic factor of 1.22. As 441 population stratification might be introduced by founder effects in Finnish participants from 442 FinnGen, we did a sensitivity analysis by removing this cohort, and observed a similar genomic 443 factor of 1.19. We also observed an LD-score intercept of 1.07, indicating an inflation mainly 444 due to polygenic architecture. Out of 11.1 million variants analyzed, 16,867 were genome-wide

significant and clustered into 100 regions, of which 7 did not overlap with loci identified in the

446 discovery or overall meta-analysis: FAM168A, AKIRIN2, LINC02103, LINC02652, SLC39A8, IRAG1,

447 and *RGS18* (**Table 2**, **Figure 2**, supplemental **Table S4**). For these 7 additional candidate loci,

the ORs ranged from 0.94-0.97 to 1.04-1.07 and the minimum MAF was 0.058.

449

450 Conditional analyses were performed with GCTA COJO at each of the 100 significant loci and

451 revealed a subset of 21 loci with multiple independent signals (supplemental **Table S5**). These

452 included 3 within novel loci: rs39840 (intronic, in ERAP1), rs28712647 (upstream of NEURL4,

VTE GWAS

453 near ALOX12) and rs7412 (nonsynonymous, in APOE). At the remaining 18 known VTE loci, 454 secondary signals at 5 loci had been previously observed, or were in LD with previously identified signals, at F5, F11, ABO, F2 and VWF,¹³ while the rest were located at EPHA3, PROS1, 455 456 FGG, the HLA region, SCARA5, TSPAN15, FADS2B, FADS1, STAB2, F10, PLCG2, THBD, and 457 A4GALT. 458 African Ancestry: The AFR-ancestry meta-analysis included 7,482 participants with VTE and 459 129,975 participants without VTE from 7 cohorts and had a genomic inflation factor of 1.05. 460 461 Here, 17.1 million variants were analyzed, of which 752 were genome-wide significant and 462 located within 13 loci, of which 2 corresponded to novel ancestry-specific signals at *RBFOX1* (OR = 0.56; MAF = 0.04) and COL6A2 (OR = 2.16; MAF = 0.011) (Table 2, Figure 2, supplemental 463 464 Table S6). 465 466 Conditional analyses were performed with GCTA COJO at each of the 13 significant loci revealed 467 3 loci with additional independent signals (supplemental **Table S7**) at *EPHA3* (with LD $r^2 < 0.02$ 468 with the primary and secondary EUR signals, using the 1000 Genomes AFR reference LD panel), 469 *PROS1* (rs6795524, LD r^2 = 0.94 with rs28479320, the lead variant from the combined meta-470 analysis located in ARL13B), and ABO (several signals). 471 472 Hispanic Ancestry: The HIS-ancestry meta-analysis included 1,720 participants with VTE and 473 57,367 participants without VTE from 4 cohorts and had a genomic inflation factor of 1.02. We 474 analyzed 11.1 million variants, of which 58 were genome-wide significant, all located at the ABO 475 locus with rs2519093 as lead variant (MAF = 0.15, OR = 1.49, P = 3.08×10^{-15}). 476 477 Comparison of Ancestry-Specific and Cross-Ancestry Meta-Analysis Results: We then 478 investigated the lead variants from the AFR- and EUR-ancestry meta-analyses at the 11 loci (all 479 known) identified in both analyses. At 5 loci (PROC, EPHA3, PROS1, VWF and THBD), none of the 480 AFR lead variants were available in the EUR analyses, due to their low frequency in EUR (MAF < 481 0.0006 for all 5 lead variants in non-Finnish Europeans according to gnomAD⁵⁷). At the

VTE GWAS

- remaining 6 loci, the lead variants from the AFR analysis were also genome wide significant inthe EUR analysis, and shared similar effect sizes.
- 484

485 Across the discovery, combined, EUR, AFR and HIS meta-analyses, we identified 135

486 independent loci (Figure 2). A summary of each locus, including LD patterns between lead

487 variants from each meta-analysis as well as independent signals and association test results

488 across all meta-analyses, is available in supplemental **Table S8**.

489

490 Gene Prioritization with TWAS and Protein QTL MR

491 <u>Transcriptome Wide Association Study</u>: Across the 6 single-tissue and 3 cross-tissues datasets

492 analyzed, we identified 166 significant ($P < 3.52 \times 10^{-6}$) and conditionally independent

493 associations with a high posterior probability of colocalization (> 0.75) between gene

494 expression and VTE risk (see supplemental **Table S9**). These associations involved 108 genes, of

495 which 77 were mapped to 46 genome-wide significant GWAS loci, leaving an additional 31

496 novel candidate genes that mapped outside of genome-wide significant GWAS loci

497 (supplemental Table S10). The candidate genes included (in chromosomal order): PRDX6,

498 LMOD1, FEZ2, PNKD, BAP1, PRKCD, CHST13, CHST13, HGFAC, NIPAL1, ARHGAP10, LHFPL2,

499 DND1, THBS2, MEST, COPG2, SYK, AAMDC, STAC3, KIF5A, NFKBIA, CINP, COMMD4, DCTPP1,

500 NFAT5, MPDU1, KDM6B, C18orf8, NPC1, RAB3D, ISOC2, and SDCBP2. At 33 GWAS loci, an

associated gene matched the gene closest to the lead variant, supporting a role as a causal

502 gene, while associated genes at the remaining 13 GWAS loci may point to genes of interest for

503 further investigations.

504

505 <u>Protein QTL Mendelian Randomization</u>: We performed agnostic MR of 1,216 plasma circulating 506 pQTL using the combined VTE meta-analysis results and identified 23 proteins with a significant 507 causal association (P < 3.98 × 10⁻⁵, **Figure 3**, supplemental **Table S11**). For 13 proteins, the gene 508 coordinates matched a genome-wide significant GWAS locus and included 5 of the novel GWAS 509 loci: *TFPI*, *ERAP2*, *TIMP3* (at the *SYN3* locus), *TIMP4* (at the *SYN2/PPARG* locus) and *ECM1* (at 510 the *FALEC* locus). Among the 10 candidate genes mapping outside of GWAS loci, *HGFAC* and

VTE GWAS

- 511 *PRDX6* were also candidate genes identified in the TWAS. The remaining 8 candidate genes 512 were: *EFEMP1*, *LCT*, *CLPS*, *MSR1*, *LGALS3*, *CD97*, *LILRB5*, *APOL3*.
- 513

514 Association of VTE-associated Variants with Hemostasis and Hematology Traits

- 515 The association of any lead or conditionally independent variant at the 135 GWAS loci with
- 516 hemostasis traits is presented in **Figure 4.A** and supplemental **Table S12**. Among the 92 novel
- 517 (replicated and candidate) loci reported above, 18 (19%) had a variant associated with 1 or
- 518 more of the 10 hemostasis traits: fibrinogen (CPS1, SLC39A8, ARHGEF28, LNPEP, PLCE1,
- 519 MS4A4A, SH2B3, MIR4708, MAP1A, HP); vWF (SLC39A8, LNPEP, ST3GAL4, SH2B3, MAP1A, HP,
- 520 APOE, FUT2); FVII (XXYLT1, JAZF1-AS1, MS4A6E, RCOR1, MAP1A); FVIII (ST3GAL4, COPZ1, HP,
- 521 APOE); PAI-1 (COPZ1, GIPR); or PT (APOH).
- 522

Next, we investigated associations of the 135 GWAS loci with hematology traits, presented in
Figure 4.B and supplemental Table S13. Across all 15 CBC measures and among the 92 novel

525 loci, we observed at least 1 association at 55 (59%) novel (replicated and candidate) loci.

526

527 Phenome-wide Association Studies

528 We performed a pheWAS of lead and conditionally independent variants at the 135 significantly 529 associated loci across 1,500 publicly available phenotypes involving European UKB participants 530 (supplemental Table S14). For each trait, only genome-wide significant variants were retrieved, 531 and we focused on traits sharing at least 10 loci with our VTE analyses (Figure 5, supplemental 532 **Table S15**), which might indicate common biological pathways. Hematology traits, in particular 533 platelet traits, shared the most loci with VTE (e.g. 33 for platelet count), consistent with our 534 observations from the larger CBC GWAS (n~750,000) sample (Figure 4.B). Several traits 535 correspond to height and weight measurements, as well as enzymes mainly produced by the 536 liver (e.g., albumin, sex-hormone binding globulin, or insulin growth factor-1), and plasma lipid-537 related traits (Apolipoprotein-A and B, HDL cholesterol, or triglycerides). Blood pressure 538 (systolic and diastolic), glycated hemoglobin, calcium, cystatin C, and C-reactive protein levels 539 were among additional traits sharing at least 10 loci with VTE. Few traits had a consistent

VTE GWAS

direction of effect with respect to VTE risk across shared loci (Figure 5). For example, out of 10
loci shared between bilirubin levels and VTE, 9 (90%) were associated with an increase of both
bilirubin levels and VTE risk. For albumin levels, glycated hemoglobin, and systolic blood
pressure, an opposite direction of effect between these traits and VTE risk was observed at
more than 75% of shared loci.

545

546 **DISCUSSION**

We identified 135 independent genomic loci and 39 additional genes from TWAS and pQTL associated with an increased or decreased risk of VTE. This reflects a substantial increase in the number of validated and candidate loci for VTE risk beyond past genetic mapping efforts.^{13,14} Our results highlight genetic variation across the rare-to-common allele frequency spectrum in multiple ancestry groups and add new evidence of biologic predictors of VTE pathogenesis for further investigation. The *in silico* interrogations provide valuable clues regarding the putative causal gene at each locus and additional insights to biological pathways shared with VTE.

555 Biological Insights

556 <u>Novel Replicated Loci</u>: Our strongest evidence supports 34 loci with novel VTE associations.

557 Except for TFPI and SERPINE2, the novel genetic loci were not in established VTE

558 pathophysiology pathways. A subset of these loci (12 loci, 35%) was associated with plasma

levels of the 10 hemostasis traits interrogated and most (26 loci, 76%) were associated with a

560 hematology trait. This contrast should be interpreted with caution as statistical power for the

561 hemostasis traits was much smaller than for the hematology traits.

562

563 While most of the novel associations reported had an OR in the range of [0.90-0.98; 1.03-1.10], 564 we were able to identify and replicate 3 uncommon variants with larger effects: an intronic 565 variant (MAF = 0.021) in the glycosyltransferase *ST3GAL4* (discovery OR = 1.21, replication OR = 566 1.18), which was also associated with increased vWF and FVIII levels, an intronic variant (MAF = 567 0.029) in the transcriptional co-activator *ZMIZ1* (discovery OR = 1.15, replication OR = 1.11), and 568 an exonic variant (MAF = 0.027) in *MAP1A* (p.Pro2349Leu, discovery OR = 0.87, replication OR =

VTE GWAS

569 0.84), which was also associated with decreased levels of vWF and fibrinogen, and had a570 protective effect against VTE.

571

572 Variants associated with hemostasis traits provide clues that the causal gene at these loci might 573 directly or indirectly perturb the coagulation cascade. For instance, XXYLT1 encodes a xylosyltransferase known to interact with coagulation factors⁵⁸ and had a nearby variant (OR 574 discovery = 1.06, OR replication = 1.06) also associated with decreased FVII levels. Another 575 576 example is FUT2, a fucosyltransferase gene involved in the synthesis of the H antigen, a building 577 block for the production of antigens within the ABO blood group. FUT2 had a downstream 578 variant (OR discovery= 0.96, OR replication = 0.96) that was also associated with decreased vWF 579 levels, mirroring results observed with vWF at the ABO locus. In addition, some variants were 580 associated with several hematology traits, suggesting common genetic regulatory pathways 581 affecting hematopoiesis, such as the replicated *RCOR1* signal on chromosome 14, and the 582 candidate gene REST on chromosome 4 identified in the combined meta-analysis, 2 genes that 583 form the transcriptional repressor CoREST, known to mediate hematopoiesis.⁵⁹

584

Among the 34 loci, 17 had TWAS evidence linking transcript expression with a gene in the locus and 3 were linked to protein measures. These results may help to prioritize biologically relevant genes for further investigations. Notably, at the *COPZ1* locus, the lead variant was associated with several CBC measures, including platelet count and red blood cell count, and the TWAS revealed an association with *NFE2*, known to regulate erythroid and megakaryocyte maturation.

591

592 <u>Other Replicated and Non-Replicated Loci:</u> Replicated variants included 2 rare variants at the 593 known *EPHA3* (intergenic, MAF = 0.0024, OR = 2.40) and *FADS2B* (intronic, MAF = 0.0047, OR = 594 0.64) loci. Among variants that failed replication, only 1 rare variant displayed significant 595 heterogeneity (P = 0.0001, *MYO16* locus), and 3 variants were located in known loci: *STAB2* was 596 previously identified as associated with VTE in an independent gene-based study using exome 597 sequencing,⁶⁰ *ARL13B* (near *PROS1*) was identified in the previous VTE GWAS from MVP,¹⁴ and

VTE GWAS

598 the JAK2 V617F variant, which is known to increase the risk of myeloproliferative neoplasm, 599 was recently identified as associated with VTE in an exome study of nearly 450,000 UKB participants.⁶¹ According to gnomAD,⁵⁷ the ARL13B variant identified is mostly observed in AFR-600 ancestry individuals (rs79324379, AFR MAF = 0.026 against MAF < 0.0003 in other ancestries) 601 602 and was not in LD with the lead variant identified in the previous MVP GWAS (rs6795524, LD r^2 603 = 0.01 in AFR); nonetheless, we would need additional information to validate this locus as a 604 truly independent signal—and not just a marker—from any strong, uncharacterized signal in 605 PROS1. Similarly, the STAB2 variant identified is mostly observed in Finns (rs142351376, Finns 606 MAF = 0.020 against MAF < 0.0003 in other ancestries); the lack of Finns in the replication likely 607 impaired our ability to replicate the association. Out of the other 12 failed replications, 5 608 involved rare variants (MAF < 0.01) that did not reach nominal significance (P < 0.05), while 6 of 609 the remaining 7 common variants reached nominal significance, suggesting that these common 610 variants might need a larger replication sample to be validated. One of these signals, located 611 between SYN2 and PPARG, was associated with the protein levels of TIMP4 in a previous 612 study.⁶² This protein, known to inhibit matrix metalloproteinases and involved in platelet 613 aggregation and recruitment,⁶³ was confirmed by the pQTL MR analysis as a gene associated 614 with VTE risk.

615

616 Novel Candidate Loci: Across the multiple interrogation approaches, we identified several score 617 of candidate loci with evidence to support their association with VTE, though not yet replicated. 618 This included 35 candidates from the combined GWAS, 7 candidates from the EUR-ancestry 619 GWAS, and 2 candidates from the AFR-ancestry GWAS. Interestingly, the 2 variants (MAF 0.04 620 and 0.011) in the AFR-ancestry population were not present in EUR-ancestry participants and 621 were associated with nearly 2-fold changes in risk of VTE. However, these 2 variants were only 622 detected in a subset of studies, which included only 882 AFR-ancestry VTE cases out of 7,482, 623 warranting additional investigations to confirm these 2 signals in *RBFOX1* (an RNA-binding 624 protein) and COL6A2 (a collagen-generating gene that contains several domains similar to VWF 625 type A domains). For the remaining candidate GWAS loci, we saw similar attributes and

VTE GWAS

associations as we did with the replicated loci. With additional replication resources in thefuture, these candidates may become fully replicated genetic associations.

In addition, the conditional analyses revealed independently associated variants mapping to
distinct genes that may be of interest for further investigations, such as *BRD3* at the *ABO* locus,

630 a chromatin reader known to associate with the hematopoietic transcription factor *GATA1*.⁶⁴ At

631 the EPHA3 locus, we also noted that the lead GWAS variant and the conditionally independent

variant mapped upstream and downstream of *PROS2P*, a protein S pseudogene that might be

- 633 of interest.
- 634

635 At these candidate loci, gene prioritized by the TWAS may also provide putative genes at these

loci. For example *ZBTB7B*, a zinc-finger protein that represses the expression of extracellular

637 matrix genes such as fibronectin and collagen⁶⁵ was identified by TWAS at the candidate locus

638 DCST2. The 31 candidate genes identified in the TWAS as well as the additional 8 from the pQTL

639 MR analyses, although lacking a significant genetic association at these loci, might indicate

640 relevant genes for future investigations. For instance, SYK is a critical platelet-activation protein

641 and tyrosine kinase inhibitors of SYK have been explored for platelet inhibition.^{66,67}

642

643 Clinical Implications

644 Current anticoagulation therapy to prevent or treat VTE operate through the modulation of 645 proteins produced in the liver (coumarin-based therapies) or through direct inhibition of 646 coagulation factors IIa (thrombin) and Xa. Although the safety profile of anticoagulation

647 treatments has evolved, bleeding remains a life-threatening off-target outcome. New

648 approaches to preventing thrombosis while minimizing bleeds are in development, including a

649 focus on contact (intrinsic) pathway proteins factor XI, factor XII, prekallikrein, and high-

650 molecular-weight kininogen.⁶⁸ Agnostic interrogations such as these may lead to discovery of

novel proteins that "break the inexorable link between antithrombotic therapy and bleeding
risk."⁶⁹

VTE GWAS

654 Remarkably, the hematology traits investigations and the pheWAS established that CBC 655 measures share a large number of loci with VTE, and platelet phenotypes in particular are the 656 most frequent traits shared with VTE variants: 51 loci were associated with either platelet 657 count, mean platelet volume, plateletcrit or platelet distribution width in the pheWAS, and 35 658 of these loci are novel, which represents more than a third of all novel genetic associations. 659 Several loci associated with VTE harbor genes with known roles in hematopoiesis and megakaryocyte development, or platelet turnover: ARID1A, REST and its co-repressor RCOR1, 660 CDK6, MECOM, RBPMS, ANGPT1, RET, NFE2, ST3GAL4, SH2B3, ZFPM2 and ZFPM1,^{59,71–79} or 661 platelet aggregation: SLC44A2, VWF, FGG, GP6, RGS18, GRK5, PIK3CB, PLCE1, PLCG2, IRAG1, 662 *TIMP4. FCER1G*, and *ALOX12*. ^{10,63,80–89} Altered platelet generation, turnover or reactivity may 663 be a feature of VTE pathogenesis. For one, past prospective studies⁹⁰ and case-control 664 studies^{91,92} suggest that enlarged platelets, as measured by MPV, are associated with VTE and 665 666 VTE outcomes. Studies of platelet function measures with VTE have been less conclusive which 667 may relate to the limitations of these studies in assessing comprehensive and standardized 668 platelet reactivity mechanisms.^{93–95} Collectively, these results suggest that treatments inhibiting 669 platelet activation such as aspirin might be beneficial in the prevention of VTE, although 670 previous studies and trials on aspirin and combinations with anticoagulants offered mixed results.⁹⁶ Different antiplatelets, such as more targeted thrombin, PAR1 or PAR4 inhibitors, or 671 672 intracellular PDE platelet signaling inhibitors like cilostazol, could be worthwhile for further 673 study in VTE prevention.

674

675 Strengths and Limitations

The major strength of this genetic discovery effort is the large sample size of the genetic variation interrogations. As the largest genetic association study of VTE to date, we were able to increase statistical power compared with previous VTE GWAS meta-analysis efforts and increase our ability to detect new associations, many of which were replicated. We were also better powered to detect less common genetic variation. The cross-ancestry meta-analyses also increased our potential to discover novel genetic associations where the allele frequency was more common in some populations compared with others.

VTE GWAS

683

684 Several limitations deserve mention. Case ascertainment varied by study and some studies 685 provided validated VTE events while others relied on information from electronic health 686 records. Further, some studies only included hospitalized VTE events and did not capture 687 events in the outpatient setting. These differences may have introduced some bias if case 688 ascertainment and hospitalization status have genetic determinants. We included all VTE cases 689 and did not stratify by provoked status in order to increase statistical power. Furthermore, 690 many of the studies had not classified the VTE events as provoked and unprovoked. In addition, 691 although the cross-ancestry approach provided benefits as described above, the numbers of 692 VTE cases were not evenly distributed by ancestry, thus reducing our ability to detect ancestry-693 specific VTE variants in the under-represented ancestry groups with more modest case counts. 694 Due to the diversity of imputation panels used by the participating studies, genetic variants had 695 variable coverage across studies which weakened our power to detect associations. Another 696 limitation of our approach that used summary GWAS statistics from meta-analyses is the 697 absence of participant-specific genotype-level information. This required us to rely on LD 698 information extracted from external datasets, which can result in variants being missed and LD 699 patterns not accurately captured. This may have introduced some bias in analyses that relied on 700 LD, such as the conditional analyses and the TWAS. Further, *in silico* work was performed using 701 external data sets such as the hemostatic factors and hematology traits summary statistics, 702 where the size (and statistical power) of the datasets varied greatly. Although different 703 significance thresholds were employed for significance, this may have biased the detection of 704 significant associations to those traits that had large sample sizes.

705

706 Conclusions

These cross-ancestry GWAS meta-analyzes have provided a list of 34 loci that replicated
discovery findings. Some of the novel loci may contribute to VTE through well-characterized
coagulation pathways while others provide new data on the role of hematology traits,
particularly platelet function. Many of the replicated loci are outside of known or currently
hypothesized pathways to thrombosis. We also provided a list of 44 new candidate loci

- 712 including candidates from the combined cross-ancestry GWAS, from the EUR-ancestry GWAS,
- 713 from the AFR-ancestry GWAS, and also 39 candidate genes from the TWAS and pQTL MR. These
- findings highlight new pathways to thrombosis and provide novel molecules that may be useful
- in the development of antithrombosis treatment that reduce bleeding adverse occurrences.

VTE GWAS

716	Acknowledgments
-----	-----------------

- 717 The INVENT Consortium would like to acknowledge all the participants across studies that
- 718 provided their health information to support these analyses.
- 719
- 720 The INVENT Consortium is supported in part by HL134894 and HL154385. The Analysis
- 721 Commons was funded by R01HL131136. Infrastructure for the CHARGE Consortium is
- supported in part by the National Heart, Lung, and Blood Institute grant R01HL105756.
- 723
- 724 Study acknowledges can be found in the **Supplemental Methods**.
- 725
- 726 The views expressed in this manuscript are those of the authors and do not necessarily
- represent the views of the National Heart, Lung and Blood Institute, the National Institute of
- Health, Department of Veterans Affairs, or the U.S. Department of Health and Human Services.

- 730
- 731
- 732
- 733

VTE GWAS

734 735	Ref	ferences
736	1.	Silverstein, M. D. et al. Trends in the incidence of deep vein thrombosis and pulmonary
737		embolism: a 25-year population-based study. Arch Intern Med 158, 585–593 (1998).
738	2.	Ghanima, W. et al. Incidence and prevalence of venous thromboembolism in Norway 2010-
739		2017. Thromb Res 195 , 165–168 (2020).
740	3.	Delluc, A. et al. Current incidence of venous thromboembolism and comparison with 1998:
741		a community-based study in Western France. Thromb Haemost 116 , 967–974 (2016).
742	4.	Smith, N. L. et al. Association of genetic variations with nonfatal venous thrombosis in
743		postmenopausal women. <i>JAMA</i> 297 , 489–498 (2007).
744	5.	Bezemer, I. D. et al. Gene variants associated with deep vein thrombosis. JAMA 299, 1306-
745		1314 (2008).
746	6.	Heit, J. A. et al. A genome-wide association study of venous thromboembolism identifies
747		risk variants in chromosomes 1q24.2 and 9q. J. Thromb. Haemost. 10, 1521–1531 (2012).
748	7.	Buil, A. et al. C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with
749		unknown protein S-independent mechanism: results from genome-wide association and
750		gene expression analyses followed by case-control studies. <i>Blood</i> 115 , 4644–4650 (2010).
751	8.	Tang, W. et al. A genome-wide association study for venous thromboembolism: the
752		extended cohorts for heart and aging research in genomic epidemiology (CHARGE)
753		consortium. Genet Epidemiol 37, 512–521 (2013).
754	9.	Germain, M. et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as
755		two susceptibility loci for venous thromboembolism. Am. J. Hum. Genet. 96, 532–542
756		(2015).

- 10. Bennett, J. A. *et al.* The choline transporter Slc44a2 controls platelet activation and
- thrombosis by regulating mitochondrial function. *Nat Commun* **11**, 3479 (2020).
- 759 11. Constantinescu-Bercu, A. et al. Activated αIIbβ3 on platelets mediates flow-dependent
- 760 NETosis via SLC44A2. *Elife* **9**, e53353 (2020).
- 761 12. Zirka, G. et al. Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF
- 762 protects against NETosis under venous shear rates. *Blood* **137**, 2256–2266 (2021).
- 13. Lindström, S. *et al.* Genomic and transcriptomic association studies identify 16 novel
- susceptibility loci for venous thromboembolism. *Blood* **134**, 1645–1657 (2019).
- 14. Klarin, D. et al. Genome-wide association analysis of venous thromboembolism identifies
- new risk loci and genetic overlap with arterial vascular disease. *Nat Genet* **51**, 1574–1579
- 767 (2019).
- 768 15. Klarin, D., Emdin, C. A., Natarajan, P., Conrad, M. F. & Kathiresan, S. Genetic Analysis of
- 769 Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates
- 770 Obesity as a Causal Risk Factor. *Circ Cardiovasc Genet* **10**, (2017).
- 16. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide
- Range of Complex Diseases of Middle and Old Age. *PLOS Medicine* **12**, e1001779 (2015).
- 17. Mitt, M. et al. Improved imputation accuracy of rare and low-frequency variants using
- population-specific high-coverage WGS-based imputation reference panel. *Eur J Hum Genet*25, 869–876 (2017).
- 18. Nagai, A. *et al.* Overview of the BioBank Japan Project: Study design and profile. *J Epidemiol*27, S2–S8 (2017).

VTE GWAS

• •

. . .

•• •

778	19. Smoller, J. W. <i>et al.</i> An eMERGE Clinical Center at Partners Personalized Medicine. <i>J Pers</i>	
779	<i>Med</i> 6 , E5 (2016).	

- 780 20. Antoni, G. et al. A multi-stage multi-design strategy provides strong evidence that the BAI3
- 781 locus is associated with early-onset venous thromboembolism. J Thromb Haemost 8, 2671–
- 782 2679 (2010).
- 783 21. Ibrahim-Kosta, M. et al. Minor allele of the factor V K858R variant protects from venous
- thrombosis only in non-carriers of factor V Leiden mutation. *Sci Rep* **9**, 3750 (2019).
- 785 22. Vázquez-Santiago, M. *et al.* Short closure time values in PFA-100[®] are related to venous
- thrombotic risk. Results from the RETROVE Study. *Thromb Res* **169**, 57–63 (2018).
- 787 23. Bild, D. E. *et al.* Multi-Ethnic Study of Atherosclerosis: objectives and design. *Am J Epidemiol*788 **156**, 871–881 (2002).
- 789 24. Souto, J. C. *et al.* Genetic determinants of hemostasis phenotypes in Spanish families.
- 790 *Circulation* **101**, 1546–1551 (2000).
- 791 25. Souto, J. C. et al. Genetic susceptibility to thrombosis and its relationship to physiological
- risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. *Am J Hum Genet*
- **67**, 1452–1459 (2000).
- 26. Hinds, D. A. *et al.* Genome-wide association analysis of self-reported events in 6135
- individuals and 252 827 controls identifies 8 loci associated with thrombosis. *Hum Mol*
- 796 *Genet* **25**, 1867–1874 (2016).
- 797 27. Zhou, W. et al. Global Biobank Meta-analysis Initiative: powering genetic discovery across
 798 human diseases. 2021.11.19.21266436

VTE GWAS

- 799 https://www.medrxiv.org/content/10.1101/2021.11.19.21266436v1 (2021)
- 800 doi:10.1101/2021.11.19.21266436.
- 801 28. Winkler, T. W. et al. Quality control and conduct of genome-wide association meta-
- 802 analyses. Nat Protoc 9, 1192–1212 (2014).
- 803 29. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
- 804 association scans. Bioinformatics 26, 2190-2191 (2010).
- 805 30. Wolfe, D., Dudek, S., Ritchie, M. D. & Pendergrass, S. A. Visualizing genomic information
- 806 across chromosomes with PhenoGram. BioData Min 6, 18 (2013).
- 807 31. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* 55, 997–1004 808
- (1999).
- 809 32. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in

810 genome-wide association studies. Nat Genet 47, 291–295 (2015).

- 811 33. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics
- 812 identifies additional variants influencing complex traits. Nat Genet 44, 369–375, S1-3

813 (2012).

814 34. Kowalski, M. H. et al. Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed)

815 Consortium whole genome sequences improves imputation quality and detection of rare

- 816 variant associations in admixed African and Hispanic/Latino populations. PLoS Genet 15,
- 817 e1008500 (2019).
- 818 35. Sabik, O. L. & Farber, C. R. RACER: A data visualization strategy for exploring multiple

819 genetic associations. 495366 https://www.biorxiv.org/content/10.1101/495366v3 (2018)

820 doi:10.1101/495366.

821	36. Mvers	. T. A.	. Chanock	. S. J.	& Machiela	. M. J.	LDlinkR: An	R Packag	e for Rapidl	v Calculating

- Linkage Disequilibrium Statistics in Diverse Populations. *Front Genet* **11**, 157 (2020).
- 823 37. Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide association
- 824 studies. *Nat Genet* **48**, 245–252 (2016).
- 38. The 1000 Genomes Project Consortium. A global reference for human genetic variation.
- 826 *Nature* **526**, 68–74 (2015).
- 827 39. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis:
- multitissue gene regulation in humans. *Science* **348**, 648–660 (2015).
- 40. Nuotio, J. et al. Cardiovascular risk factors in 2011 and secular trends since 2007: the
- 830 Cardiovascular Risk in Young Finns Study. *Scand J Public Health* **42**, 563–571 (2014).
- 41. Wright, F. A. *et al.* Heritability and genomics of gene expression in peripheral blood. *Nat*
- 832 *Genet* **46**, 430–437 (2014).
- 42. Feng, H. et al. Leveraging expression from multiple tissues using sparse canonical
- 834 correlation analysis and aggregate tests improves the power of transcriptome-wide
- association studies. *PLOS Genetics* **17**, e1008973 (2021).
- 43. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic
- Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 838 44. Zhao, H. *et al.* Proteome-wide Mendelian randomization in global biobank meta-analysis
- reveals multi-ancestry drug targets for common diseases. 2022.01.09.21268473 (2022)
- 840 doi:10.1101/2022.01.09.21268473.
- 45. de Vries, P. S. et al. A meta-analysis of 120 246 individuals identifies 18 new loci for
- fibrinogen concentration. *Hum. Mol. Genet.* **25**, 358–370 (2016).

- 46. Smith, N. L. *et al.* Genetic predictors of fibrin D-dimer levels in healthy adults. *Circulation*
- **123**, 1864–1872 (2011).
- 47. de Vries, P. S. et al. A genome-wide association study identifies new loci for factor VII and
- 846 implicates factor VII in ischemic stroke etiology. *Blood* **133**, 967–977 (2019).
- 48. Sabater-Lleal, M. et al. Genome-Wide Association Transethnic Meta-Analyses Identifies
- 848 Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma
- 849 Levels. *Circulation* **139**, 620–635 (2019).
- 49. Sennblad, B. et al. Genome-wide association study with additional genetic and post-
- transcriptional analyses reveals novel regulators of plasma factor XI levels. *Hum. Mol.*
- 852 *Genet.* **26**, 637–649 (2017).
- 50. Huang, J. *et al.* Genome-wide association study for circulating tissue plasminogen activator
- levels and functional follow-up implicates endothelial STXBP5 and STX2. *Arterioscler*.
- 855 Thromb. Vasc. Biol. **34**, 1093–1101 (2014).
- 51. Huang, J. *et al.* Genome-wide association study for circulating levels of PAI-1 provides novel
- 857 insights into its regulation. *Blood* **120**, 4873–4881 (2012).
- 858 52. Tang, W. et al. Genetic associations for activated partial thromboplastin time and
- 859 prothrombin time, their gene expression profiles, and risk of coronary artery disease. Am J
- 860 *Hum Genet* **91**, 152–162 (2012).
- 53. Chen, M.-H. et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667
- 862 Individuals from 5 Global Populations. *Cell* **182**, 1198-1213.e14 (2020).

- 863 54. Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure. 2020.08.10.244293
- 864 https://www.biorxiv.org/content/10.1101/2020.08.10.244293v1 (2020)
- 865 doi:10.1101/2020.08.10.244293.
- 55. Yang, J. *et al.* Genomic inflation factors under polygenic inheritance. *European Journal of*
- 867 *Human Genetics* **19**, 807 (2011).
- 56. Riis, J., Nordestgaard, B. G. & Afzal, S. α1 Antitrypsin Z allele and risk of venous
- thromboembolism in the general population. *J Thromb Haemost* **20**, 115–125 (2022).
- 870 57. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
- 871 141,456 humans. *Nature* **581**, 434–443 (2020).
- 58. Minamida, S. et al. Detection of UDP-D-xylose: alpha-D-xyloside alpha 1--
- 873 >3xylosyltransferase activity in human hepatoma cell line HepG2. J Biochem 120, 1002–
- 874 1006 (1996).
- 59. Saleque, S., Kim, J., Rooke, H. M. & Orkin, S. H. Epigenetic regulation of hematopoietic
- 876 differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. *Mol Cell*
- 877 **27**, 562–572 (2007).
- 878 60. Desch, K. C. et al. Whole-exome sequencing identifies rare variants in STAB2 associated
- with venous thromboembolic disease. *Blood* **136**, 533–541 (2020).
- 61. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants.
- 881 *Nature* **599**, 628–634 (2021).
- 62. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 63. Radomski, A. et al. Identification, regulation and role of tissue inhibitor of
- metalloproteinases-4 (TIMP-4) in human platelets. *Br J Pharmacol* **137**, 1330–1338 (2002).

885	64.	Lamonica, J. M. et al. Bromodomain protein Brd3 associates with acetylated GATA1 to
886		promote its chromatin occupancy at erythroid target genes. Proc Natl Acad Sci U S A 108,
887		E159-168 (2011).
888	65.	Widom, R. L., Lee, J. Y., Joseph, C., Gordon-Froome, I. & Korn, J. H. The hcKrox gene family
889		regulates multiple extracellular matrix genes. Matrix Biol 20, 451–462 (2001).
890	66.	Perrella, G. et al. Role of Tyrosine Kinase Syk in Thrombus Stabilisation at High Shear. Int J
891		Mol Sci 23 , 493 (2022).
892	67.	Zheng, T. J. et al. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated
893		platelet signaling and function. Am J Physiol Cell Physiol 320 , C902–C915 (2021).
894	68.	Fredenburgh, J. C. & Weitz, J. I. New anticoagulants: Moving beyond the direct oral
895		anticoagulants. J Thromb Haemost 19, 20–29 (2021).
896	69.	Mackman, N., Bergmeier, W., Stouffer, G. A. & Weitz, J. I. Therapeutic strategies for
897		thrombosis: new targets and approaches. Nat Rev Drug Discov 19, 333–352 (2020).
898	70.	Hoffman, M. Coagulation in Liver Disease. Semin Thromb Hemost 41 , 447–454 (2015).
899	71.	Han, L. et al. Chromatin remodeling mediated by ARID1A is indispensable for normal
900		hematopoiesis in mice. <i>Leukemia</i> 33 , 2291–2305 (2019).
901	72.	Scheicher, R. et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell
902		activation. <i>Blood</i> 125 , 90–101 (2015).
903	73.	Schulze, H. & Shivdasani, R. A. Mechanisms of thrombopoiesis. J Thromb Haemost 3, 1717-
904		1724 (2005).

VTE GWAS


- 905 74. Maslah, N., Cassinat, B., Verger, E., Kiladjian, J.-J. & Velazquez, L. The role of LNK/SH2B3
- 906 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
- 907 *Leukemia* **31**, 1661–1670 (2017).
- 908 75. Mancini, E. et al. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic
- and erythroid progenitors. *EMBO J* **31**, 351–365 (2012).
- 910 76. Krosl, J. et al. A mutant allele of the Swi/Snf member BAF250a determines the pool size of
- 911 fetal liver hemopoietic stem cell populations. *Blood* **116**, 1678–1684 (2010).
- 912 77. Ayoub, E. et al. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1
- 913 transcription. *Nat Commun* **9**, 4239 (2018).
- 914 78. Fonseca-Pereira, D. *et al.* The neurotrophic factor receptor RET drives haematopoietic stem
- 915 cell survival and function. *Nature* **514**, 98–101 (2014).
- 916 79. Gregory, G. D. et al. FOG1 requires NuRD to promote hematopoiesis and maintain lineage
- 917 fidelity within the megakaryocytic-erythroid compartment. *Blood* **115**, 2156–2166 (2010).
- 918 80. Keramati, A. R. et al. Genome sequencing unveils a regulatory landscape of platelet
- 919 reactivity. Nat Commun 12, 3626 (2021).
- 920 81. Mitsui, T. et al. ALOX12 mutation in a family with dominantly inherited bleeding diathesis. J
- 921 Hum Genet **66**, 753–759 (2021).
- 922 82. Fukami, K. Structure, regulation, and function of phospholipase C isozymes. J Biochem 131,
- 923 293–299 (2002).
- 924 83. Johnson, A. D. et al. Genome-wide meta-analyses identifies seven loci associated with
- platelet aggregation in response to agonists. *Nat Genet* **42**, 608–613 (2010).

VTE GWAS


- 926 84. Moore, S. F., Smith, N. R., Blair, T. A., Durrant, T. N. & Hers, I. Critical roles for the
- 927 phosphatidylinositide 3-kinase isoforms p110β and p110γ in thrombopoietin-mediated
- 928 priming of platelet function. *Sci Rep* **9**, 1468 (2019).
- 85. Kuijpers, M. J. E. et al. Platelet CD40L Modulates Thrombus Growth Via Phosphatidylinositol
- 930 3-Kinase β, and Not Via CD40 and IkB Kinase α. Arterioscler Thromb Vasc Biol **35**, 1374–
- 931 1381 (2015).
- 932 86. Rodriguez, B. A. T. et al. A Platelet Function Modulator of Thrombin Activation Is Causally
- 933 Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling. *Am J Hum Genet*
- **107**, 211–221 (2020).
- 87. Antl, M. *et al.* IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and
 thrombus formation. *Blood* **109**, 552–559 (2007).
- 937 88. Schinner, E., Salb, K. & Schlossmann, J. Signaling via IRAG is essential for NO/cGMP-
- 938 dependent inhibition of platelet activation. *Platelets* **22**, 217–227 (2011).
- 939 89. van Geffen, J. P. et al. High-throughput elucidation of thrombus formation reveals sources
- 940 of platelet function variability. *Haematologica* **104**, 1256–1267 (2019).
- 941 90. Braekkan, S. K. *et al.* Mean platelet volume is a risk factor for venous thromboembolism:
- 942 the Tromsø Study, Tromsø, Norway. J Thromb Haemost **8**, 157–162 (2010).
- 943 91. Ghaffari, S. et al. Prognostic value of platelet indices in patients with acute pulmonary
- 944 thromboembolism. *J Cardiovasc Thorac Res* **12**, 56–62 (2020).
- 945 92. Farah, R., Nseir, W., Kagansky, D. & Khamisy-Farah, R. The role of neutrophil-lymphocyte
- 946 ratio, and mean platelet volume in detecting patients with acute venous thromboembolism.
- 947 J Clin Lab Anal **34**, e23010 (2020).

948	93. Puurunen, M. K., Hwang, SJ., O'Donnell, C. J., Tofler, G. & Johnson, A. D. Platelet function
949	as a risk factor for venous thromboembolism in the Framingham Heart Study. Thromb Res
950	151 , 57–62 (2017).
951	94. Sokol, J., Skerenova, M., Ivankova, J., Simurda, T. & Stasko, J. Association of Genetic
952	Variability in Selected Genes in Patients With Deep Vein Thrombosis and Platelet
953	Hyperaggregability. Clin Appl Thromb Hemost 24, 1027–1032 (2018).
954	95. Panova-Noeva, M. et al. Comprehensive platelet phenotyping supports the role of platelets
955	in the pathogenesis of acute venous thromboembolism - results from clinical observation
956	studies. <i>EBioMedicine</i> 60 , 102978 (2020).
957	96. Diep, R. & Garcia, D. Does aspirin prevent venous thromboembolism? Hematology Am Soc
958	Hematol Educ Program 2020 , 634–641 (2020).
959	
960	
961	
962	
963	
964	
965	
966	
967	
968	
969	
970	
971	
972	
973	

- 974 Figures and legends
- 975
- 976
- 977 Figure 1: Analyses Workflow



987 Figure 2: Genetic loci associated with VTE




- 989 This figure presents the 130 loci significantly associated with VTE identified across all 4 meta-analyses: the Discovery (in blue), the
- 990 overall meta-analysis (in green), the analysis restricted to individuals of European ancestry (in red) and the analysis restricted to
- 991 individuals of African ancestry (in black). Novel loci are represented with circles and known loci with diamonds.
- 992
- 993
- 994
- 995
- 996

997 Figure 3: Significant associations of protein QTL Mendelian Randomization


Exposure	Outcome		OR	95% CI	Р
F5	VTE		5.22	[4.83, 5.63]	0
F2 (SeqId_4157_2)	VTE	-	3.18	[2.96, 3.43]	1×10^{-206}
F2 (SeqId_5316_54)	VTE	_ _	1.74	[1.45, 2.1]	5×10^{-9}
F11	VTE	_ _	1.5	[1.28, 1.75]	4×10^{-7}
GSS	VTE	-	1.12	[1.07, 1.19]	1×10^{-5}
GP6	VTE	•	1.07	[1.05, 1.08]	4×10^{-23}
TIMP3	VTE	•	1.07	[1.05, 1.08]	3×10^{-12}
LGALS3	VTE	•	1.06	[1.03, 1.08]	4×10^{-6}
LILRB5	VTE	•	1.04	[1.02, 1.06]	2×10^{-5}
LCT	VTE	•	1.04	[1.02, 1.05]	4×10^{-9}
ECM1	VTE		1.03	[1.02, 1.04]	4×10^{-8}
HGFAC	VTE	•	1.02	[1.01, 1.03]	8×10^{-6}
ERAP2	VTE	E Contraction of the second se	0.975	[0.966, 0.984]	6×10^{-8}
CLPS	VTE		0.963	[0.945, 0.98]	4×10^{-5}
APOL3	VTE	•	0.961	[0.946, 0.975]	2×10^{-7}
TIMP4	VTE		0.958	[0.94, 0.976]	6×10^{-6}
PRDX6	VTE	•	0.946	[0.923, 0.97]	9×10^{-6}
MSR1	VTE	•	0.937	[0.91, 0.966]	3×10^{-5}
EFEMP1	VTE	•	0.918	[0.896, 0.941]	9×10^{-12}
PLEK	VTE	•	0.894	[0.872, 0.916]	4×10^{-19}
CD97	VTE	+	0.881	[0.836, 0.927]	
TFPI	VTE	-	0.804	[0.743, 0.869]	5×10^{-8}
PROS1	VTE		0.776	[0.695, 0.867]	
KLKB1	VTE		0.345	[0.304, 0.391]	4×10^{-61}
	-	1 2 3 4 5 6			
		Odds Ratio (95% Confidence Interval)			

998



1000 statistics.

1001



1003 Figure 4: VTE genetic loci shared with hemostatic factors and blood traits

1004


1005 (A) Number of known and novel VTE loci shared with each of the 10 hemostatic factors investigated. (B) Same analysis with

1006 complete blood count traits: PLT (platelet count), MPV (mean platelet volume), RBC (red blood cell count), MCV (mean corpuscular

1007 volume), HCT (hematocrit), MCH (mean corpuscular hemoglobin), MCHC (MCH concentration), HGB (hemoglobin concentration),

1008 RDW (red cell distribution width), WBC (white blood cell count), MONO (monocyte count), NEU (neutrophil count), EOS (eosinophil

1009 count), BASO (basophil count), LYM (lymphocyte count).



1010 Figure 5: PheWAS traits sharing at least 10 loci with VTE

1011

Percentage of loci shared with VTE also sharing the same effect direction

This figure presents the pheWAS traits sharing at least 10 loci with VTE. Shape and color represent one of 5 categories: Complete
Blood Count (CBC) traits, lipid traits, liver enzyme, height and weight traits, or other (if the trait did not fit in one of the
aforementioned categories). The x-axis indicates the number of loci shared between VTE and the pheWAS trait, while the y-axis
indicates the proportion of loci where the direction of effect was identical between the pheWAS trait and VTE. As a result, traits
close to 100% have the same direction of effect than VTE at most shared loci, while traits close to 0% have an opposite direction
than VTE at most shared loci

VTE GWAS

1019

1020

1021 Table 1: 68 Lead variants from the Discovery meta-analysis successfully replicated

rsID	CHR:POS:EA:NEA	EAF.Disc	OR.Disc	P.Disc	OR.Repl	P.Repl	Locus.Context	Locus.Gene
rs9442580	1:9339467:T:C	0.1551	1.06	1.83E-08	1.03	9.70E-05	intergenic	H6PD;SPSB1
rs3767812	1:118155620:A:G	0.2437	1.05	9.64E-11	1.06	1.03E-20	intronic	TENT5C
rs6025	1:169519049:T:C	0.0259	3.02	8.40E-811	3.59	9.29E-3103	exonic	<i>F5</i> (p.Q534Q)
rs2842700	1:207282149:A:C	0.1092	1.11	5.95E-17	1.12	1.19E-25	intronic	C4BPA
rs3811444	1:248039451:T:C	0.3324	0.96	5.70E-09	0.95	1.53E-20	exonic	TRIM58 (p.T374M)
rs7600986	2:68636923:A:T	0.2819	1.06	3.54E-12	1.05	9.18E-19	intergenic	PLEK;FBXO48
rs182293241	2:128029746:A:G	0.0195	1.89	1.83E-27	1.55	0.0001063	intronic	ERCC3
rs6719550	2:188272460:T:C	0.6639	1.04	7.56E-09	1.05	1.93E-17	intronic	CALCRL
rs715	2:211543055:T:C	0.7022	0.95	3.51E-09	0.95	1.43E-17	UTR3	CPS1
rs13412535	2:224874874:A:G	0.2047	1.06	3.05E-10	1.08	1.10E-36	intronic	SERPINE2
rs13084580	3:39188182:T:C	0.1076	1.09	2.89E-15	1.08	9.10E-22	exonic	<i>CSRNP1</i> (p.G18S)
rs562281690	3:90177913:T:G	0.0024	2.01	6.45E-15	2.40	8.68E-31	intergenic	EPHA3;NONE
rs62282204	3:138584405:T:C	0.5784	0.96	1.87E-08	0.98	6.73E-05	intergenic	PIK3CB;LINC01391
rs7613621	3:169191186:A:G	0.4467	1.04	3.21E-09	1.03	5.33E-09	intronic	МЕСОМ
rs710446	3:186459927:T:C	0.5799	0.96	5.92E-11	0.96	1.41E-16	exonic	<i>KNG1</i> (p.I581I)
rs6797948	3:194784705:T:C	0.7983	1.06	2.99E-11	1.05	7.59E-16	intergenic	LINC01968;XXYLT1
rs6826579	4:83785031:T:C	0.7914	1.05	2.38E-08	1.03	2.44E-07	intronic	SEC31A
rs17010957	4:86719165:T:C	0.8581	1.06	3.99E-09	1.05	1.00E-11	intronic	ARHGAP24
rs2066864	4:155525695:A:G	0.2585	1.23	1.98E-172	1.23	1.94E-284	UTR3	FGG
rs3756011	4:187206249:A:C	0.3903	1.23	7.48E-198	1.24	9.26e-398	intronic	F11
rs16867574	5:38708554:T:C	0.6673	0.95	2.78E-11	0.95	5.67E-16	ncRNA_intronic	OSMR-AS1
rs38032	5:96321887:T:C	0.6049	1.04	8.74E-09	1.03	1.49E-09	intronic	LNPEP
rs9268881	6:32431606:A:T	0.5727	0.96	4.17E-10	0.97	6.73E-09	intergenic	HLA-DRA;HLA-DRB5
rs145294670	6:34622561:A:AG	0.1385	1.06	6.11E-10	1.04	6.89E-06	intronic	ILRUN
rs9390460	6:147694334:T:C	0.4957	0.95	2.49E-13	0.95	1.01E-20	intronic	STXBP5
rs67694436	8:6654220:T:C	0.3486	0.96	3.94E-08	0.98	0.0001105	intergenic	AGPAT5;XKR5
rs2685417	8:27807434:C:G	0.2562	1.06	1.57E-14	1.06	2.84E-25	intronic	SCARA5
rs6993770	8:106581528:A:T	0.7142	1.08	4.48E-25	1.09	3.55E-48	intronic	ZFPM2
rs35208412	9:99194509:A:AT	0.8298	1.09	1.56E-08	1.04	5.54E-06	intergenic	ZNF367;HABP4
rs505922	9:136149229:T:C	0.6334	0.74	1.11E-425	0.69	1.55E-1043	intronic	ABO
rs1887091	10:14535113:T:C	0.4936	0.96	4.77E-08	0.98	0.001107	intergenic	MIR1265;FAM107B
rs17490626	10:71218646:C:G	0.1136	0.80	1.02E-79	0.80	3.23E-160	intronic	TSPAN15
rs16937003	10:80938499:A:G	0.0287	1.15	1.07E-08	1.11	2.11E-11	intronic	ZMIZ1
rs2274224	10:96039597:C:G	0.4414	1.04	2.55E-09	1.03	1.29E-10	exonic	PLCE1 (p.R1267P)
rs10886430	10:121010256:A:G	0.8897	0.89	7.34E-25	0.88	2.76E-64	intronic	GRK5
rs11032074	11:32993887:A:G	0.7792	1.05	5.37E-09	1.03	3.24E-06	intronic	QSER1
rs1799963	11:46761055:A:G	0.0136	2.05	2.19E-135	2.09	6.86E-420	UTR3	F2
rs141687379	11:56666822:A:G	0.9953	0.52	3.56E-31	0.64	1.06E-42	intronic	FADS2B
rs174551	11:61573684:T:C	0.6583	1.07	1.65E-19	1.07	4.90E-35	intronic	FADS1
rs35257264	11:126296816:T:C	0.0212	1.21	2.88E-14	1.18	2.28E-24	intronic	ST3GAL4
rs1558519	12:6153738:A:G	0.6175	0.93	7.73E-24	0.92	1.42E-55	intronic	VWF
rs7311483	12:9053661:T:C	0.3589	0.96	2.74E-09	0.97	2.73E-07	intergenic	A2ML1;PHC1
rs6580981	12:54723028:A:G	0.5081	0.96	3.71E-09	0.95	2.26E-23	intronic	COPZ1
rs3184504	12:111884608:T:C	0.4520	1.05	1.18E-11	1.04	3.30E-12	exonic	<i>SH2B3</i> (p.T178T)
rs3211752	13:113787459:A:G	0.5527	0.95	1.69E-12	0.94	3.49E-25	intronic	F10
rs57035593	14:92268096:T:C	0.3202	1.07	1.08E-20	1.07	2.64E-38	intronic	TC2N
rs8013957	14:103140254:T:C	0.3699	1.04	5.33E-09	1.03	2.23E-07	intronic	RCOR1
rs55707100	15:43820717:T:C	0.0270	0.87	2.90E-08	0.84	2.49E-27	exonic	<i>MAP1A</i> (p.P2349L)
		0.0270	0.07	2.302.00	0.0 r	2	CAOTINO	

VTE GWAS

rs59442804	15:60899031:G:GAAAT	0.6438	0.96	4.67E-08	0.97	5.42E-10	ncRNA_intronic	RORA-AS1
rs12443808	16:30996871:C:G	0.4668	1.06	3.89E-14	1.03	1.85E-07	UTR5	HSD3B7
rs56943275	16:81898152:T:G	0.2446	1.08	4.15E-13	1.07	1.20E-26	intronic	PLCG2
rs28634651	16:88553198:T:C	0.6191	1.06	9.20E-13	1.04	7.62E-14	intronic	ZFPM1
rs6503222	17:1977862:A:G	0.6188	1.05	1.59E-12	1.04	5.21E-06	intronic	SMG6
rs7225756	17:6893691:A:G	0.4877	0.96	3.57E-08	0.98	1.20E-06	ncRNA_intronic	ALOX12-AS1
rs62054822	17:43927708:A:G	0.8028	0.95	6.39E-09	0.95	7.11E-19	ncRNA_intronic	MAPT-AS1
rs142140545	17:64191540:CTATT:C	0.1169	0.93	2.27E-08	0.95	7.83E-07	intergenic	CEP112;APOH
rs59277920	19:6077231:A:G	0.8210	0.94	1.47E-09	0.96	8.52E-06	intronic	RFX2
rs8110055	19:10739143:A:C	0.2000	0.89	5.36E-44	0.89	6.50E-70	intronic	SLC44A2
rs34783010	19:46180414:T:G	0.2132	0.95	3.25E-09	0.96	4.87E-10	intronic	GIPR
rs1688264	19:49209560:T:G	0.5341	0.96	2.07E-10	0.96	3.02E-15	downstream	FUT2
rs1654425	19:55538980:T:C	0.1468	0.91	2.65E-18	0.94	4.21E-14	exonic	<i>GP6</i> (p.S192S)
rs79388863	20:23168500:A:G	0.1521	0.92	1.74E-18	0.92	4.48E-27	intergenic	LINC00656;NXT1
rs6060288	20:33772243:A:G	0.3417	1.12	8.19E-54	1.13	1.52E-102	intronic	MMP24-AS1-EDEM2
rs4820093	22:33160208:T:C	0.2693	1.05	1.04E-08	1.04	5.39E-14	intronic	SYN3
rs9611844	22:43115776:C:G	0.1286	1.10	2.09E-21	1.07	7.54E-20	intronic	A4GALT
rs3002416	23:39710195:T:C	0.3638	0.95	2.20E-18	0.93	2.23E-23	intergenic	MIR1587;BCOR
rs6048	23:138633280:A:G	0.7215	1.07	1.09E-25	1.08	1.59E-46	exonic	<i>F9</i> (p.T156T)
rs2084408	23:154346709:T:G	0.3764	0.94	5.36E-19	0.94	6.27E-09	intronic	BRCC3
000								

.024 CHR: chromosome; POS: position (hg19 build); EA: effect allele; NEA: non effect allele; EAF: effect allele frequency; OR: odd

1025 ratio; P: P-value. Results from the discovery are in presented in columns suffixed with "Disc", while results from the replication

1026 are in columns suffixed with "Repl". Novel genetic associations are indicated as bold gene names.

VTE GWAS

1051 Table 2: Additional 44 candidate novel loci identified in the Overall, European and African meta-

IUJZ UNUIUJUJU	1052	analyses
----------------	------	----------

1053

CHR:POS:EA:NEA	EAF	EFFECT	SE	OR	Р	Locus.context	Locus.Gene
ntified in the overall m	eta-ana	lysis					
1:27107263:T:TC	0.9248	0.0759	0.0132	1.08	9.61E-09	UTR3	ARID1A
1:77945635:A:G	0.1938	0.0424	0.0072	1.04	4.28E-09	intronic	AK5
1:109818158:CT:C	0.7627	-0.0449	0.0066	0.96	8.95E-12	UTR3	CELSR2
1:150496127:CA:C	0.5468	0.0426	0.0076	1.04	2.36E-08	intergenic	FALEC;ADAMTSL4
1:154991389:T:C	0.7448	-0.0346	0.0063	0.97	3.70E-08	intronic	DCST2
1:161188893:T:G	0.9182	0.0654	0.0106	1.07	7.70E-10	UTR3	FCER1G
1:196809316:T:TAA	0.5434	0.0415	0.0074	1.04	2.44E-08	intergenic	CFHR1;CFHR4
2:65086804:T:C	0.0542	-0.0713	0.0128	0.93	2.52E-08	ncRNA_intronic	LINC01800
2:198545250:C:G	0.1919	-0.0412	0.0071	0.96	7.27E-09	intergenic	RFTN2;MARS2
3:156798732:A:G	0.6205	0.0382	0.0060	1.04	1.46E-10	intergenic	LINC02029;LINC00880
4:7903763:C:G	0.1504	0.0492	0.0081	1.05	1.03E-09	intronic	AFAP1
4:57778645:A:G	0.1963	0.0389	0.0070	1.04	2.26E-08	intronic	REST
5:72957088:T:C	0.5245	-0.0328	0.0057	0.97	1.04E-08	intronic	ARHGEF28
5:132426851:G:GTT	0.0810	-0.0659	0.0110	0.94	2.43E-09	intronic	HSPA4
6:25536937:T:C	0.4331	0.0357	0.0055	1.04	1.01E-10	intronic	CARMIL1
6:29943688:G:C	0.7331	-0.0405	0.0063	0.96	1.43E-10	ncRNA intronic	HCG9
7:28259233:T:C			0.0070		1.40E-10	ncRNA intronic	JAZF1-AS1
			0.0105				LOC101929128;LOC157273
8:23373680:A:G					5.77E-09		ENTPD4;SLC25A37
8:30402817:A:G					2.52E-08		RBPMS
							ANGPT1
							MLLT10
							RAB18;MKX
11:16251251:A:T							SOX6
							MS4A4A;MS4A6E
							ZBTB16
							SNX19
							LINC02324;MIR4708
							LINC00924;LOC105369212
							NDE1
							DHODH;HP
							CFDP1
							C16orf74
							TAOK1
							RAB4B
-	-		-	1 04	6 88F-09	intergenic	LINC01680;RGS18
							BANK1;SLC39A8
							LINC02103;LSP1P3
							AKIRIN2
							LINC02652
							IRAG1;CTR9
						-	FAM168A
				1.05	2.002.00	apstream	
-	-		-	0 5 6	1 525 00	intropic	
							RBFOX1
21:4/525005:A:G	0.0114	0.9527	0.1/25	2.60	4.11E-U8	intronic	COL6A2
	htified in the overall m 1:27107263:T:TC 1:77945635:A:G 1:109818158:CT:C 1:150496127:CA:C 1:154991389:T:C 1:161188893:T:G 1:196809316:T:TAA 2:65086804:T:C 2:198545250:C:G 3:156798732:A:G 4:7903763:C:G 4:7903763:C:G 4:57778645:A:G 5:72957088:T:C 5:132426851:G:GTT 6:25536937:T:C 6:29943688:G:C 7:28259233:T:C 8:9178821:C:G 8:108291878:C:G 10:21907016:T:C 10:21907016:T:C 10:21907016:T:C 10:27881308:A:T 11:160088159:C:G 11:114003415:T:C 11:130779668:T:C 14:65794352:T:C 15:96101018:A:G 16:75738114:C:G 16:75738114:C:G 16:75738114:C:G 16:7578651:A:G 17:27833678:A:AGATT 19:41287674:T:C <i>vel loci identified in the</i> 1:192104320:C:G 4:103146888:A:C 5:28379046:T:G	htified in the overall meta-anal 1:27107263:T:TC 0.9248 1:77945635:A:G 0.1938 1:109818158:CT:C 0.7627 1:150496127:CA:C 0.5468 1:154991389:T:C 0.7448 1:161188893:T:G 0.9182 1:196809316:T:TAA 0.5434 2:65086804:T:C 0.0542 2:198545250:C:G 0.1919 3:156798732:A:G 0.6205 4:7903763:C:G 0.1963 5:72957088:T:C 0.5245 5:132426851:G:GTT 0.0810 6:25536937:T:C 0.4331 6:29943688:G:C 0.7331 7:28259233:T:C 0.7453 8:9178821:C:G 0.1105 8:23373680:A:G 0.3089 8:30402817:A:G 0.2391 8:108291878:C:G 0.2492 10:21907016:T:C 0.6920 10:27881308:A:T 0.2726 11:16251251:A:T 0.6077 11:60088159:C:G 0.3635 11:114003415:T:C 0.3112 11:130779668:T:C 0.3512 16:7738114:C:G 0.9728 16:720791	tified in the overall meta-analysis 1:27107263:T:TC 0.9248 0.0759 1:77945635:A:G 0.1938 0.0424 1:109818158:CT:C 0.7627 -0.0449 1:150496127:CA:C 0.5468 0.0426 1:154991389:T:C 0.7448 -0.0346 1:168809316:T:TAA 0.5434 0.0415 2:65086804:T:C 0.0542 -0.0713 2:198545250:C:G 0.1919 -0.0412 3:156798732:A:G 0.6205 0.0382 4:7903763:C:G 0.1963 0.0389 5:72957088:T:C 0.5245 -0.0328 5:132426851:G:GTT 0.0810 -0.0659 6:25536937:T:C 0.7331 -0.0405 7:28259233:T:C 0.7453 0.0449 8:9178821:C:G 0.3089 -0.0341 10:21907016:T:C 0.6920 -0.0341 10:21907016:T:C 0.6920 -0.0341 10:21907016:T:C 0.3635 0.0315 11:160088159:C:G 0.3635 0.0315 11:160088159:C:G 0.3635 0.0344 11:130779668:T:C 0.312	thified in the overall meta-analysis 1:27107263:T:TC 0.9248 0.0759 0.0132 1:77945635:A:G 0.1938 0.0424 0.0072 1:109818158:CT:C 0.7627 -0.0449 0.0066 1:150496127:CA:C 0.5468 0.0426 0.0076 1:154991389:T:C 0.7448 -0.0346 0.0063 1:161188893:T:G 0.9182 0.0654 0.0106 1:196809316:T:TAA 0.5434 0.0415 0.0074 2:65086804:T:C 0.0542 -0.0713 0.0128 2:198545250:C:G 0.1919 -0.0412 0.0071 3:156798732:A:G 0.6205 0.0382 0.0060 4:7903763:C:G 0.1963 0.0389 0.0070 5:132426851:G:GTT 0.810 -0.0659 0.0110 6:25536937:T:C 0.4311 0.0357 0.0063 7:28259233:T:C 0.7453 0.0449 0.0070 8:9178821:C:G 0.7311 -0.0405 0.0065 8:108291878:C:G 0.2391 0.0365 0.0065 8:108291878:C:G 0.2395 0.0064 <t< td=""><td>thified in the overall meta-analysis 1:27107263:T:TC 0.9248 0.0759 0.0132 1.08 1:77945635:A:G 0.1938 0.0424 0.0072 1.04 1:109818158:CT:C 0.7627 -0.0449 0.0066 0.96 1:150496127:CA:C 0.5468 0.0026 0.0075 1.04 1:1514991389:T:C 0.7448 -0.0346 0.0063 0.97 1:1611888931:G 0.9182 0.0654 0.0104 1.04 2:65086804:T:C 0.0542 -0.0713 0.0128 0.93 2:198545250:C:G 0.1919 -0.0412 0.0071 0.96 3:156798732:A:G 0.6205 0.0382 0.0081 1.05 4:57778645:A:G 0.1963 0.0389 0.0071 1.04 5:72957088:T:C 0.5245 -0.0328 0.0057 0.97 5:132426851:G:GTT 0.810 -0.0455 0.0110 0.94 6:25536937:T:C 0.7331 -0.0405 0.0063 0.96 7:28259233:T:C 0.7453</td><td>thified in the overall meta-analysis 1:27107263:T:TC 0.9248 0.0759 0.0132 1.08 9.61E-09 1:17945635:A:G 0.1938 0.0424 0.0072 1.04 4.28E-09 1:109818158:CT:C 0.7627 -0.0449 0.0066 0.96 8.95E-12 1:150496127:CA:C 0.5468 0.0426 0.0076 1.04 2.36E-08 1:154991389:T:C 0.7448 -0.0346 0.0063 0.97 3.70E-08 1:161888931:T:G 0.9182 0.0654 0.0106 1.07 7.77E-09 2:55086804:T:C 0.0542 -0.0713 0.0128 0.93 2.52E-08 2:198545250:C:G 0.1919 -0.0412 0.0071 0.96 7.27E-09 3:156798732:A:G 0.6205 0.0382 0.0057 0.97 1.04E-08 5:72957088:T:C 0.5245 -0.0328 0.0057 0.97 1.04E-08 5:12426881:G:GTT 0.810 -0.0659 0.0110 0.94 2.43E-09 6:25363937:T:C 0.4331 -0.0405 0.066 0.97 5.77E-09 8:304028</td><td>trificial in the overall meta-analysis 1:77107263:T:TC 0.9248 0.0759 0.0132 1.08 9.61E-09 UTR3 1:77945635:A:G 0.1938 0.0424 0.0072 1.04 4.28E-09 intronic 1:1509818158:CT:C 0.7627 0.0449 0.0066 0.96 8.95E-12 UTR3 1:1514991389:T:C 0.7448 0.0346 0.0061 1.07 7.70E-10 UTR3 1:1514899317:G 0.7448 0.0415 0.0074 1.04 2.44E-08 intergenic 2:65086804:T:C 0.0542 0.0112 0.0071 0.96 7.27E-09 intronic 2:15854250:C:G 0.1504 0.0492 0.0081 1.04 1.46E-10 intergenic 3:156798732:A:G 0.6205 0.0382 0.0070 1.04 2.48E-09 intronic 5:72957088:T:C 0.5454 -0.0328 0.057 0.97 1.04E-08 intronic 6:25943688:G:C 0.7331 -0.0405 0.063 0.96 1.43E-10 intronic 6:25943688:G:C 0.3389 -0.0375 1.005 1.40E</td></t<>	thified in the overall meta-analysis 1:27107263:T:TC 0.9248 0.0759 0.0132 1.08 1:77945635:A:G 0.1938 0.0424 0.0072 1.04 1:109818158:CT:C 0.7627 -0.0449 0.0066 0.96 1:150496127:CA:C 0.5468 0.0026 0.0075 1.04 1:1514991389:T:C 0.7448 -0.0346 0.0063 0.97 1:1611888931:G 0.9182 0.0654 0.0104 1.04 2:65086804:T:C 0.0542 -0.0713 0.0128 0.93 2:198545250:C:G 0.1919 -0.0412 0.0071 0.96 3:156798732:A:G 0.6205 0.0382 0.0081 1.05 4:57778645:A:G 0.1963 0.0389 0.0071 1.04 5:72957088:T:C 0.5245 -0.0328 0.0057 0.97 5:132426851:G:GTT 0.810 -0.0455 0.0110 0.94 6:25536937:T:C 0.7331 -0.0405 0.0063 0.96 7:28259233:T:C 0.7453	thified in the overall meta-analysis 1:27107263:T:TC 0.9248 0.0759 0.0132 1.08 9.61E-09 1:17945635:A:G 0.1938 0.0424 0.0072 1.04 4.28E-09 1:109818158:CT:C 0.7627 -0.0449 0.0066 0.96 8.95E-12 1:150496127:CA:C 0.5468 0.0426 0.0076 1.04 2.36E-08 1:154991389:T:C 0.7448 -0.0346 0.0063 0.97 3.70E-08 1:161888931:T:G 0.9182 0.0654 0.0106 1.07 7.77E-09 2:55086804:T:C 0.0542 -0.0713 0.0128 0.93 2.52E-08 2:198545250:C:G 0.1919 -0.0412 0.0071 0.96 7.27E-09 3:156798732:A:G 0.6205 0.0382 0.0057 0.97 1.04E-08 5:72957088:T:C 0.5245 -0.0328 0.0057 0.97 1.04E-08 5:12426881:G:GTT 0.810 -0.0659 0.0110 0.94 2.43E-09 6:25363937:T:C 0.4331 -0.0405 0.066 0.97 5.77E-09 8:304028	trificial in the overall meta-analysis 1:77107263:T:TC 0.9248 0.0759 0.0132 1.08 9.61E-09 UTR3 1:77945635:A:G 0.1938 0.0424 0.0072 1.04 4.28E-09 intronic 1:1509818158:CT:C 0.7627 0.0449 0.0066 0.96 8.95E-12 UTR3 1:1514991389:T:C 0.7448 0.0346 0.0061 1.07 7.70E-10 UTR3 1:1514899317:G 0.7448 0.0415 0.0074 1.04 2.44E-08 intergenic 2:65086804:T:C 0.0542 0.0112 0.0071 0.96 7.27E-09 intronic 2:15854250:C:G 0.1504 0.0492 0.0081 1.04 1.46E-10 intergenic 3:156798732:A:G 0.6205 0.0382 0.0070 1.04 2.48E-09 intronic 5:72957088:T:C 0.5454 -0.0328 0.057 0.97 1.04E-08 intronic 6:25943688:G:C 0.7331 -0.0405 0.063 0.96 1.43E-10 intronic 6:25943688:G:C 0.3389 -0.0375 1.005 1.40E

¹⁰⁵⁴

1055 CHR: chromosome; POS: position (hg19 build); EA: effect allele; NEA: non effect allele; EAF: effect allele frequency; SE: Standard

1056 Error of Effect; OR: odd ratio; P: P-value.